<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2804245220
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        HERCEPTIN 120 mg/ml Solution For Injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Trastuzumab
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        120
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        6252.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="F. Hoffmann-La Roche Ltd." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            F. Hoffmann-La Roche Ltd.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 718]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ARAC HEALTHCARE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ROCHE
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Herceptin contains the active substance trastuzumab, which is a monoclonal antibody. Monoclonal antibodies attach to specific proteins or antigens. Trastuzumab is designed to bind selectively to an antigen called human epidermal growth factor receptor 2 (HER2). HER2 is found in large amounts on the surface of some cancer cells where it stimulates their growth. When Herceptin binds to HER2 it stops the growth of such cells and causes them to die.<br />Your doctor may prescribe Herceptin for the treatment of breast cancer when:</strong></p><p dir="ltr"><strong> You have early breast cancer, with high levels of a protein called HER2.<br /> You have metastatic breast cancer (breast cancer that has spread beyond the original tumour) with high levels of HER2. Herceptin may be prescribed in combination with the chemotherapy medicines paclitaxel or docetaxel as first treatment for metastatic breast cancer or it may be prescribed alone if other treatments have proved unsuccessful. It is also used in combination with medicines called aromatase inhibitors with patients with high levels of HER2 and hormone receptor-positive metastatic breast cancer (cancer that is sensitive to the presence of female sex hormones).</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not use Herceptin if:<br /> you are allergic to trastuzumab (the active substance of Herceptin), murine (mouse) proteins, or any of the other ingredients of this medicine (listed in section 6).<br /> you have severe breathing problems at rest due to your cancer or if you need oxygen treatment.<br />Warnings and precautions<br />Your doctor will closely supervise your therapy.<br />Heart checks<br />Treatment with Herceptin alone or with a taxane may affect the heart, especially if you have ever used an anthracycline (taxanes and anthracyclines are two other kinds of medicine used to treat cancer). The effects may be moderate to severe and could cause death. Therefore, your heart function will be checked before, during (every three months) and after (up to two to five years) treatment with Herceptin. If you develop any signs of heart failure (i.e. inadequate pumping of blood by the heart), your heart function may be checked more frequently (every six to eight weeks), you may receive treatment for heart failure or you may have to stop Herceptin treatment.<br />Talk to your doctor, pharmacist or nurse before you are given Herceptin if:<br /> you have had heart failure, coronary artery disease, heart valve disease (heart murmurs), high blood pressure, taken any high blood pressure medicine or are currently taking any high blood pressure medicine.</strong></p><p dir="ltr"><strong> you have ever had or are currently using a medicine called doxorubicin or epirubicin (medicines used to treat cancer). These medicines (or any other anthracyclines) can damage heart muscle and increase the risk of heart problems with Herceptin.<br /> you suffer from breathlessness, especially if you are currently using a taxane. Herceptin can cause breathing difficulties, especially when it is first given. This could be more serious if you are already breathless. Very rarely, patients with severe breathing difficulties before treatment have died when they were given Herceptin.<br /> you have ever had any other treatment for cancer.<br />If you receive Herceptin with any other medicine to treat cancer, such as paclitaxel, docetaxel, an aromatase inhibitor, carboplatin or cisplatin you should also read the patient information leaflets for these products.<br />Children and adolescents<br />Herceptin is not recommended for anyone under the age of 18 years.<br />Other medicines and Herceptin<br />Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.<br />It may take up to 7 months for Herceptin to be removed from the body. Therefore you should tell your doctor, pharmacist or nurse that you have had Herceptin if you start any new medicine in the 7 months after stopping treatment.<br />Pregnancy<br /> If you are pregnant, think you may be pregnant or are planning to have a baby, you must tell your doctor, pharmacist or nurse before taking this medicine.<br /> You should use effective contraception during treatment with Herceptin and for at least 7 months after treatment has ended.<br />Your doctor will advise you of the risks and benefits of taking Herceptin during pregnancy. In rare cases, a reduction in the amount of (amniotic) fluid that surrounds the developing baby within the womb has&nbsp;been observed in pregnant women receiving Herceptin. This condition may be harmful to your baby in the womb and has been associated with the lungs not developing fully resulting in foetal death.</strong></p><p dir="ltr">&nbsp;</p><p><strong>Breast-feeding</strong></p><p dir="ltr"><strong>Do not breast-feed your baby during Herceptin therapy and for 7 months after the last dose of Herceptin as Herceptin may pass to your baby through your breast milk.<br />Ask your doctor, pharmacist or nurse for advice before taking any medicine.</strong></p><p dir="ltr"><br /><strong>Driving and using machines<br />Herceptin may affect your ability to drive a car or operate machines. If during treatment, you experience symptoms, such as dizziness, sleepiness, chills or fever, you should not drive or use machines until these symptoms disappear.</strong></p><p dir="ltr"><br /><strong>Sodium<br />Herceptin contains less than 1 mmol of sodium (23 mg) per dose, that is to say essentially sodium-free.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Before starting the treatment your doctor will determine the amount of HER2 in your tumour. Only patients with a large amount of HER2 will be treated with Herceptin. Herceptin should only be given by a doctor or nurse.<br />Two different types (formulations) of Herceptin exist:<br /> one is given as an infusion into a vein (intravenous infusion)<br /> the other is given as an injection under the skin (subcutaneous injection).<br />It is important to check the product labels to ensure that the correct formulation is being given as prescribed. Herceptin subcutaneous fixed dose formulation is not for intravenous use and should be given as a subcutaneous injection only.</strong></p><p dir="ltr"><strong>Your doctor may consider switching your Herceptin intravenous treatment to Herceptin subcutaneous treatment (and vice versa) if considered appropriate for you.<br />In order to prevent medication errors it is also important to check the vial labels to ensure that the medicine being prepared and given is Herceptin (trastuzumab) and not another trastuzumab-containing product (e.g. trastuzumab emtansine or trastuzumab deruxtecan).<br />The recommended dose is 600 mg. Herceptin is given as a subcutaneous injection (under the skin) over 2 to 5 minutes every three weeks.<br />The injection site should be alternated between the left and right thigh. New injections should be given at least 2.5 cm away from an old site. No injection should be given into areas where the skin is red, bruised, tender or hard.<br />If other medicines for subcutaneous use are used during the treatment course with Herceptin, a different injection site should be used.<br />Herceptin should not be mixed or diluted with other products.</strong></p><p dir="ltr"><strong>If you stop using Herceptin<br />Do not stop using this medicine without talking to your doctor first. All doses should be taken at the right time every three weeks. This helps your medicine work as well as it can.<br />It may take up to 7 months for Herceptin to be removed from your body. Therefore your doctor may decide to continue to check your heart functions, even after you finish treatment.<br />If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</strong></p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p dir="ltr"><strong>Like all medicines, this medicine can cause side effects, although not everybody gets them. Some of these side effects may be serious and may lead to hospitalisation.</strong></p><p dir="ltr"><strong>During treatment with Herceptin, chills, fever and other flu like symptoms may occur. These are very common (may affect more than 1 in 10 people). Other symptoms are: feeling sick (nausea), vomiting, pain, increased muscle tension and shaking, headache, dizziness, breathing difficulties, high or low blood pressure, heart rhythm disturbances (palpitations, heart fluttering or irregular heart beat), swelling of the face and lips, rash and feeling tired. Some of these symptoms can be serious and some patients have died (see the section &ldquo;Warnings and precautions&rdquo;).<br />Your doctor or nurse will check for side effects during the administration and for 30 minutes after the first administration and for 15 minutes after other administrations.</strong><br />&nbsp;</p><p dir="ltr"><strong>Serious side effects<br />Other side effects can occur at any time during treatment with Herceptin. Tell a doctor or nurse straight away, if you notice any of the following side effects:<br /> Heart problems can sometimes occur during treatment and occasionally after treatment has stopped and can be serious. They include weakening of the heart muscle possibly leading to heart failure, inflammation of the lining around the heart and heart rhythm disturbances. This can lead to symptoms such as breathlessness (including breathlessness at night), cough, fluid retention (swelling) in the legs or arms, palpitations (heart fluttering or irregular heart beat) (see section 2. Heart checks).<br />Your doctor will monitor your heart regularly during and after treatment but you should tell your doctor immediately if you notice any of the above symptoms.<br /> Tumour lysis syndrome (a group of metabolic complications occurring after cancer treatment characterized by high blood levels of potassium and phosphate, and low blood levels of calcium). Symptoms may include kidney problems (weakness, shortness of breath, fatigue and confusion), heart problems (fluttering of the heart or a faster or slower heartbeat), seizures, vomiting or diarrhoea and tingling in the mouth, hands or feet</strong></p><p dir="ltr"><br /><strong>If you experience any of the above symptoms when your treatment with Herceptin has finished, you should see your doctor and tell them that you have previously been treated with Herceptin.<br />Two different types (formulations) of Herceptin exist:</strong></p><p dir="ltr"><strong> one is given as an infusion into a vein over 30 to 90 minutes<br /> the other is given as a subcutaneous injection over 2 to 5 minutes.</strong></p><p dir="ltr"><br /><strong>In the clinical study comparing these two formulations, infections and cardiac events leading to hospitalisation were more frequent with the subcutaneous formulation. There were also more local reactions at the site of injection and more increases in blood pressure. Other side effects were similar.<br />Very common side effects of Herceptin: may affect more than 1 in 10 people<br /> infections<br /> diarrhoea<br /> constipation<br /> heartburn (dyspepsia)<br /> fatigue<br /> skin rashes<br /> chest pain<br /> abdominal pain<br /> joint pain<br /> low counts of red blood cells and white blood cells (which help fight infection) sometimes with fever<br /> muscle pain<br /> conjunctivitis<br /> watery eyes<br /> nose bleeds<br /> runny nose<br /> hair loss<br /> tremor<br /> hot flush<br /> dizziness<br /> nail disorders</strong></p><p dir="ltr"><strong> weight loss<br /> loss of appetite<br /> inability to sleep (insomnia)<br /> altered taste<br /> low platelet count<br /> bruising<br /> numbness or tingling of the fingers and toes, which occasionally may extend to the rest of the limb<br /> redness, swelling or sores in your mouth and/or throat<br /> pain, swelling, redness or tingling of hands and/or feet<br /> breathlessness<br /> headache<br /> cough<br /> vomiting<br /> nausea</strong></p><p dir="ltr"><strong>Common side effects of Herceptin: may affect up to 1 in 10 people<br /> allergic reactions<br /> dry mouth and skin<br /> throat infections<br /> dry eyes<br /> bladder and skin infections<br /> sweating<br /> inflammation of the breast<br /> feeling weak and unwell<br /> inflammation of the liver<br /> anxiety<br /> kidney disorders<br /> depression<br /> increased muscle tone or tension (hypertonia)<br /> asthma<br /> infection of lungs<br /> pain in the arms and/or legs<br /> lung disorders<br /> itchy rash<br /> back pain<br /> sleepiness (somnolence)<br /> neck pain<br /> haemorrhoids<br /> bone pain<br /> itchiness<br /> acne<br /> leg cramps</strong></p><p dir="ltr"><br /><strong>Uncommon side effects of Herceptin: may affect up to 1 in 100 people</strong></p><p dir="ltr"><strong> deafness<br /> bumpy rash<br /> wheezing<br /> inflammation or scarring of the lungs</strong></p><p dir="ltr"><br /><strong>Rare side effects of Herceptin: may affect up to 1 in 1,000 people<br /> jaundice<br /> anaphylactic reactions</strong></p><p dir="ltr"><br /><strong>Other side effects that have been reported with Herceptin use: frequency cannot be estimated from the available data<br /> abnormal or impaired blood clotting<br /> high potassium levels<br /> swelling or bleeding at the back of the eyes<br /> shock<br /> abnormal heart rhythm<br /> respiratory distress<br /> respiratory failure<br /> acute accumulation of fluid in the lungs<br /> acute narrowing of the airways<br /> abnormally low oxygen levels in the blood<br /> difficulty in breathing when lying flat<br /> liver damage<br /> swelling of the face, lips and throat<br /> kidney failure</strong></p><p dir="ltr"><strong> abnormally low levels of fluid around baby in womb<br /> failure of the lungs of the baby to develop in the womb<br /> abnormal development of the kidneys of the baby in the womb</strong></p><p dir="ltr"><br /><strong>Some of the side effects you experience may be due to your underlying breast cancer. If you receive Herceptin in combination with chemotherapy, some of them may also be due to the chemotherapy.<br />If you get any side effects, talk to your doctor, pharmacist or nurse.</strong></p><p dir="ltr"><br /><strong>Reporting of side effects<br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the outer carton and on the vial label after EXP. The expiry date refers to the last day of that month.<br />Store in a refrigerator (2&deg;C &ndash; 8&deg;C).<br />Keep the vial in the outer carton to protect from light.<br />Do not freeze.<br />Upon opening of the vial, the solution should be used immediately.</strong></p><p dir="ltr"><strong>Do not use this medicine if you notice any particulate matter or discoloration prior to administration.<br />Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong> The active substance is trastuzumab. One vial of 5 mL contains 600 mg of trastuzumab.<br /> The other ingredients are recombinant human hyaluronidase (rHuPH20), L-histidine, L-histidine hydrochloride monohydrate, &alpha;,&alpha;-trehalose dihydrate, L-methionine, polysorbate 20, water for injections.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Herceptin is a solution for injection that is supplied in a glass vial with a butyl rubber stopper containing 5 mL (600 mg) of trastuzumab. The solution is clear to opalescent and colourless to yellowish.
Each carton contains one vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>F. Hoffmann-La Roche Ltd,&nbsp;</strong></p><p dir="ltr"><strong>Grenzacherstrasse 124</strong></p><p dir="ltr"><strong>CH-4070 Basel</strong></p><p dir="ltr"><strong>Switzerland.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in January 2022 

To report any side effect(s):

Saudi Arabia:
 The National Pharmacovigilance and Drug Safety Centre (NPC)
o Fax: +966-11-205-7662
o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.
o SFDA call center: 19999
o E-mail: npc.drug@sfda.gov.sa
o Website: https://ade.sfda.gov.sa

 Other GCC States:
 Please contact the relevant competent authority.
Council of Arab Health Ministers
This is a Medicament
 Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.
 Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament.
 The doctor and the pharmacist are the experts in medicines, their benefits and risks.
 Do not by yourself interrupt the period of treatment prescribed for you.
 Do not repeat the same prescription without consulting your doctor.
 Keep all medicaments out of reach of children.
Council of Arab Health Ministers
Union of Arab Pharmacists
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="rtl"><strong>يحتوي هيرسيبتين على المادة الفعالة تراستوزوماب وهي عبارة عن جسم مضاد أحادي النسيلة. ترتبط الأجسام المضادة أحادية النسيلة ببروتينات ومستضدات معينة. وصُمم تراستوزوماب ليرتبط بشكل انتقائي بمستضد يطلق عليه المستقبل الثاني لعامل نمو البشرة البشري (HER2). ويوجد هذا المستضد في كميات كبيرة على سطح بعض الخلايا السرطانية حيث يحفز نموها. عند ارتباط هيرسيبتين بمستضد HER2 فإنه يمنع نمو هذه الخلايا السرطانية ويتسبب في موتها.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>قد يصف لك طبيبك هيرسيبتين لعلاج سرطان الثدي في الحالات التالية:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>إذا كنت مصاب بسرطان الثدي في مرحلة مبكرة، مع وجود مستويات عالية من بروتين يسمى HER2.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>في حالة الإصابة بسرطان الثدي النقيلي (سرطان الثدي الذي ينتشر خارج الورم الأصلي) مع وجود مستويات عالية من HER2. يمكن وصف هيرسيبتين مع أدوية العلاج الكيميائي باكليتاكسيل (paclitaxel) أو دوسيتاكسيل (Docetaxel) كعلاج أولي لسرطان الثدي النقيلي، أو يمكن وصفه بمفرده إذا ثبت أن العلاجات الأخرى غير ناجحة. كما أنه يستخدم مع الأدوية التي تسمى مثبطات الهرمونات مع المرضى الذين يعانون من مستويات عالية من HER2، وسرطان الثدي النقيلي إيجابي المستقبلات الهرمونية (السرطان الذي يكون حساس لوجود الهرمونات الجنسية الأنثوية).</strong></p></li></ul><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>لا تستخدم هيرسيبتين في الحالات التالية:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>إن كنت تعاني من الحساسية تجاه تراستوزوماب (المادة الفعالة في هيرسيبتين)، أو البروتينات الجرذية (الفأرية) أو أي من المكونات الأخرى في هذا الدواء (المدرجة في القسم 6).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إن كنت تعاني من مشاكل حادة في التنفس في أوقات الراحة نتيجة لإصابتك بالسرطان أو إن كنت تحتاج للعلاج بالأكسجين.</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>التحذيرات والاحتياطات</strong></p><p dir="rtl"><strong>سوف يقوم طبيبك بالإشراف على علاجك عن كثب.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>فحوصات القلب</strong></p><p dir="rtl"><strong>العلاج بالهيرسيبتين وحده أو مع التاكسين قد يؤثر على القلب، وخاصة إذا كنت قد استخدمت من قبل أنثراسيكلين (taxanes و anthracyclines هما أنواع أخرى من الأدوية المستخدمة في علاج السرطان). قد تكون الآثار معتدلة إلى حادة، ويمكن أن تسبب الوفاة. لذلك سيتم فحص وظائف القلب قبل بداية العلاج، وخلال العلاج (كل ثلاثة أشهر) وبعد العلاج (ما يصل إلى 2-5 سنوات) بالهيرسيبتين. إذا ظهرت أي أعراض تدل على قصور القلب (أي عدم كفاية ضخ الدم من القلب)، يمكن فحص وظائف القلب بشكل أكثر تكرارا (كل ستة إلى ثمانية أسابيع)، قد تتلقى علاجا لقصور القلب أو قد تضطر إلى إيقاف العلاج بالهيرسيبتين.</strong><br />&nbsp;</p><p dir="rtl"><strong>تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل البدء في تناول هيرسيبتين:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>إذا كنت تعاني من قصور القلب، ومرض الشريان التاجي، وأمراض صمامات القلب (لغط القلب)، وارتفاع ضغط الدم، تناول أي من أدوية ارتفاع ضغط الدم أو إذا كنت تتناول حاليا أي من أدوية ضغط الدم المرتفع.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كنت تتناول دواء يسمى دوكسوروبيسين (doxorubicin) أو ايبيروبايسين (epirubicin) وهي أدوية المستخدمة لعلاج السرطان في أي وقت مضى أو في الوقت الحاضر. يمكن لهذه الأدوية (أو أي أدوية أنثراسيكلين أخرى) أن تؤدي إلى تلف عضلة القلب وزيادة مخاطر حدوث مشاكل القلب مع هيرسيبتين.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كنت تعاني من ضيق في التنفس، وخاصة إذا كنت تستخدم حاليا التاكسين. هيرسيبتين يمكن أن يسبب صعوبات في التنفس، وخصوصا عندما يعطى لأول مرة. هذا يمكن أن يكون أكثر خطورة إذا كنت بالفعل تعاني من ضيق في التنفس. نادرا جدا ما يسبب تناول هيرسيبتين وفاة المرضى الذين يعانون من صعوبات شديدة في التنفس قبل بداية العلاج.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إذا كنت قد تلقيت في أي وقت مضى أي علاج آخر لمرض السرطان.</strong></p></li></ul><p dir="rtl"><strong>إذا كنت تتلقى هيرسيبتين مع أي دواء آخر لعلاج السرطان، مثل باكليتاكسيل، دوسيتاكسيل، مثبط الأروماتاز، كاربوبلاتين أو سيسبلاتين يجب عليك أيضا قراءة نشرة معلومات المرضى لهذه الأدوية.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>الأطفال والمراهقين</strong></p><p dir="rtl"><strong>لا ينصح باستخدام هيرسيبتين لأي شخص تحت 18 سنة.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>تفاعل هيرسيبتين مع الأدوية أخرى</strong></p><p dir="rtl"><strong>أخبر طبيبك أو الصيدلي أو الممرضة إن كنت تتناول أو تناولت مؤخرًا أو قد تتناول أية أدوية أخرى.</strong></p><p dir="rtl"><strong>قد تحتاج لفترة تصل إلى سبعة أشهر للتخلص من آثار هيرسيبتين بجسمك. ولذا، عليك أن تخبر طبيبك أو الممرضة أنك تتناول هيرسيبتين إن بدأت في تعاطي دواء جديد خلال فترة سبعة أشهر بعد التوقف عن العلاج.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>الحمل</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>إن كنت حاملًا أو تشكين في أنك حاملًا أو تخططين للإنجاب، عليك اطلاع طبيبك أو الصيدلي أو الممرضة قبل تناول هذا الدواء.&nbsp;</strong></p></li><li dir="rtl"><p dir="rtl"><strong>عليك استخدام وسائل فعالة لمنع الحمل خلال فترة العلاج باستخدام هيرسيبتين ولمدة لا تقل عن 7 أشهر من انتهاء العلاج.</strong></p></li></ul><p dir="rtl"><strong>سوف يخبرك طبيبك بمخاطر وفوائد تناول هيرسيبتين خلال فترة الحمل. في حالات نادرة، لوحظ انخفاض في كمية السائل (الأمنيوسي) الذي يحيط بالجنين داخل الرحم في النساء الحوامل اللواتي يتلقين العلاج بالهيرسيبتين. قد يكون هذا الوضع ضار بطفلك في الرحم ويرتبط بعدم نمو الرئتين بشكل كامل مما يؤدي إلى وفاة الجنين.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>الرضاعة الطبيعية</strong></p><p dir="rtl"><strong>لا تقومين بالرضاعة الطبيعية أثناء العلاج بالهيرسيبتين. أيضا لا تقومين بالرضاعة لمدة 7 أشهر بعد الجرعة الأخيرة من هيرسيبتين. وذلك لأن هيرسيبتين يمكن أن ينتقل إلى طفلك عن طريق حليب الثدي.</strong></p><p dir="rtl"><strong>اسأل طبيبك أو الصيدلي أو الممرضة للحصول على المشورة قبل تناول أي دواء.</strong></p><p>&nbsp;</p><p dir="RTL"><strong>قد يؤثر استخدامك لهيرسيبتين على قدرتك على قيادة السيارة أو تشغيل الآلات. إذا واجهت أي أعراض أثناء العلاج مثل الدوخة ,النوم , &nbsp;القشعريرة أو الحمى، ينبغي عليك عدم قيادة السيارة أو استخدام الآلات حتى زوال تلك الأعراض.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الصوديوم</strong></p><p dir="RTL"><strong>يحتوي هيرسيبتين على أقل من 1 مللي مول من الصوديوم (23 مجم) لكل جرعة ، وهذا يعني أنه خالٍ من الصوديوم</strong></p><p><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>قبل البدء في العلاج، سيحدد طبيبك كمية المستقبل الثاني لعامل نمو البشرة البشري (HER2) في الورم لديك، وسيخضع المرضى ذوي النسب المرتفعة منه فقط للعلاج باستخدام هيرسيبتين. وينبغي إعطاء هيرسيبتين فقط من قبل الطبيب أو الممرضة.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>يوجد نوعين مختلفين (تركيبات) من هيرسيبتين:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>يعطى أحدهما عن طريق الحقن في الوريد (وريديًا)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ويعطى الاخر عن طريق الحقن تحت الجلد (حقن تحت الجلد)</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>من المهم التأكد من الملصقات الموجودة على كل منتج لضمان وصف التركيبة الصحيحة على النحو الموصوف. فلا يجب حقن الجرعة المحددة من هيرسيبتين للحقن تحت الجلد وريديًا ويجب أن تعطى عن طريق الحقن تحت الجلد فقط.</strong></p><p dir="rtl"><strong>قد يقوم طبيبك في تبديل علاجك باستخدام هيرسيبتين للحقن الوريدي إلى العلاج باستخدام هيرسيبتين للحقن تحت الجلد (أو العكس) حسبما يكون مناسبًا لك.</strong></p><p dir="rtl"><strong>&nbsp;من أجل منع الأخطاء الدوائية، من المهم أيضا التحقق من الملصقات على الأمبول للتأكد من أن الدواء الذي يتم تحضيره وإعطاءه هو هيرسيبتين (تراستوزوماب) وليس تراستوزوماب إيمتانسين.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>الجرعة الموصى بها هي 600 ملجم، ويعطى هيرسيبتين عن طريق الحقن تحت الجلد على مدار دقيقتين إلى 5 دقائق كل ثلاثة أسابيع.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>يجب تغيير موضع الحقن ما بين الفخذ الأيمن والأيسر، وتعطى الجرعة الجديدة على بعد 2.5 سم على الأقل من الموضع القديم. ولا يجب إعطاء أية حقن في مناطق الجلد المصابة بالاحمرار أو الكدمات أو التورم أو الصلابة.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>إذا تم استخدام أي أدوية أخرى تعطى عن طريق الحقن تحت الجلد خلال فترة العلاج باستخدام هيرسيبتين، يجب استخدام موضع حقن آخر مختلف.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>لا ينبغي خلط هيرسيبتين أو تخفيفه مع غيره من الأدوية.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>التوقف عن استخدام هيرسيبتين&nbsp;</strong></p><p dir="rtl"><strong>لا تتوقف عن استخدام هذا الدواء دون التحدث إلى طبيبك أولاً. يجب أن تؤخذ جميع الجرعات في الوقت المناسب كل ثلاثة أسابيع. وهذا يساعد على عمل الدواء بأكثر فعالية ممكنة.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>قد تحتاج لفترة تصل إلى 7 أشهر للتخلص من آثار هيرسيبتين بجسدك، ولذا فقد يقرر طبيبك الاستمرار في إجراء فحوصات وظائف القلب حتى بعد انتهاء العلاج.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>إن كان لديك المزيد من الاستفسارات حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي أو الممرضة.</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>مثل جميع الأدوية، يمكن أن يسبب هيرسيبتين آثارًا جانبية، على الرغم من عدم حدوثها لكل الاشخاص. بعض هذه الآثار الجانبية قد تكون خطيرة وقد تؤدي إلى دخول المستشفى.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>خلال العلاج باستخدام هيرسيبتين قد تتعرض للإصابة بالقشعريرة، الحمى وغيرها من الأعراض التي تشبه أعراض الأنفلونزا. هذه الأعراض تكون شائعة جدا (قد تؤثر على أكثر من 1 في كل 10 أشخاص). الأعراض الأخرى هي: الشعور بالإعياء (الغثيان)، والتقيؤ، والألم، وزيادة توتر العضلات والرعشة، والصداع، والدوخة، وصعوبة في التنفس، والصفير عند التنفس، وارتفاع أو انخفاض ضغط الدم، أو اضطرابات ضربات القلب (خفقان القلب أو ارتعاش القلب أو عدم انتظام ضربات القلب)، أو تورم الوجه والشفتين والطفح الجلدي والشعور بالتعب. قد تكون بعض هذه الأعراض خطيرة وقد تؤدي إلى وفاة بعض المرضى (انظر قسم &quot;التحذيرات والاحتياطات&quot;).</strong></p><p>&nbsp;</p><p dir="RTL"><strong>ستخضع للملاحظة من قبل الطبيب أو الممرض خلال فترة حقن الجرعة ولمدة نص ساعة بعد بدء الجرعة الأولى ولمدة ربع ساعة بعد بدء الجرعات الأخرى.</strong></p><p dir="RTL"><strong>الاعراض الجانبية الخطيرة</strong></p><p dir="RTL"><strong>قد تحدث بعض الاعراض الجانبية الاخرى اثناء العلاج بهيرسيبتين, وهي غير مرتبطة بالتنقيط فقط.</strong></p><p dir="RTL"><strong>اخبر طبيبك او الممرضة فورا, اذا لاحظت ايا من تلك الاعراض الجانبية:</strong></p><p dir="rtl"><strong>قد تحدث بعض المشاكل المتعلقة بالقلب أحيانًا بعد التوقف عن العلاج وقد يكون ذلك خطيرًا، ويشمل ذلك ضعف عضلة القلب مما يمكن أن يؤدي إلى الإصابة بقصور القلب، والتهاب (تورم واحمرار وسخونة وألم) للبطانة المغلفة للقلب وأيضًا عدم انتظام ضربات القلب. ويقد يؤدي ذلك إلى بعض الأعراض مثل:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>ضيق التنفس (بما في ذلك ضيق التنفس أثناء الليل)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>السعال</strong></p></li><li dir="rtl"><p dir="rtl"><strong>احتباس السوائل (تورم) في الساقين أو الذراعين</strong></p></li><li dir="rtl"><p dir="rtl"><strong>خفقان القلب (عدم انتظام الضربات).</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>سيراقب طبيبك قلبك بشكل منتظم خلال العلاج وبعده، ولكن عليك اطلاع طبيبك فورًا إذا لاحظت أي من الأعراض المذكورة أعلاه.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>إذا تعرضت لأي من الأعراض المذكورة أعلاه بعد انتهاء فترة العلاج باستخدام هيرسيبتين، يجب عليك مراجعة طبيبك واخباره بأنك قد سبق وخضعت للعلاج باستخدام هيرسيبتين.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>هناك نوعين مختلفين(تركيبات) من هيرسيبتين:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>أحدهما يعطى كحقن في الوريد لمدة تتراوح من 30 إلى 90 دقيقة.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ويعطى النوع الاخر عن طريق الحقن تحت الجلد لمدة تتراوح من دقيقتين إلى 5 دقائق.</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>في الدراسة السريرية التي تقارن بين هاتين التركيبين، كانت الالتهابات ومشاكل القلب التي أدت الى دخول المستشفى أكثر تكرارًا أثناء تناول التركيبة التي تحقن تحت الجلد. وكانت هناك أيضًا المزيد من ردود الفعل الموضعية أكثر في مكان الحقن وزيادة أكثر في ضغط الدم، وكانت الآثار الجانبية الأخرى متشابهة.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>الآثار الجانبية الشائعة للغاية عند استخدام هيرسيبتين: (قد تؤثر على أكثر من 1 من كل 10 أشخاص)</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>العدوى</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الإسهال</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الإمساك</strong></p></li><li dir="rtl"><p dir="rtl"><strong>&nbsp;ارتجاع المريء</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التعب</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الطفح الجلدي</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم في الصدر</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم في البطن</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم في المفاصل</strong></p></li><li dir="rtl"><p dir="rtl"><strong>انخفاض عدد خلايا الدم الحمراء وخلايا الدم البيضاء (التي تساعد على مكافحة العدوى) وأحيانًا تكون مصاحبة بحمى</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم في العضلات</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التهاب الملتحمة</strong></p></li><li dir="rtl"><p dir="rtl"><strong>دمع العين</strong></p></li><li dir="rtl"><p dir="rtl"><strong>نزيف الأنف</strong></p></li><li dir="rtl"><p dir="rtl"><strong>سيلان الأنف</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تساقط الشعر</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الرجفة</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الهبات الساخنة</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الدوار</strong></p></li><li dir="rtl"><p dir="rtl"><strong>اضطرابات الأظافر</strong></p></li><li dir="rtl"><p dir="rtl"><strong>فقدان الوزن</strong></p></li><li dir="rtl"><p dir="rtl"><strong>فقدان الشهية</strong></p></li><li dir="rtl"><p dir="rtl"><strong>عدم القدرة على النوم (الأرق)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تغيير في المذاق</strong></p></li><li dir="rtl"><p dir="rtl"><strong>انخفاض عدد الصفائح الدموية</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الإصابة بالكدمات</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الخدر أو الوخز في أصابع اليدين والقدمين</strong></p></li><li dir="rtl"><p dir="rtl"><strong>احمرار، تورم أو ألم في الفم و/أو الحلق</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم، تورم، احمرار أو وخز في اليدين و/أو القدمين</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ضيق التنفس</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الصداع</strong></p></li><li dir="rtl"><p dir="rtl"><strong>السعال</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التقيؤ</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الغثيان</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>الآثار الجانبية الشائعة عند استخدام هيرسيبتين: قد تؤثر على 1 من كل 10 أشخاص</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>ردود الأفعال التحسسية</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التهابات الحلق</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التهابات المثانة والجلد</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الهربس النطاقي</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التهاب الثدي</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التهاب الكبد</strong></p></li><li dir="rtl"><p dir="rtl"><strong>اضطرابات الكلى</strong></p></li><li dir="rtl"><p dir="rtl"><strong>زيادة شد أو توتر العضلات (فرط التوتر)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم في الذراعين و/أو الساقين</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الطفح الجلدي المسبب للحكة</strong></p></li><li dir="rtl"><p dir="rtl"><strong>النعاس (نعاس)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>البواسير</strong></p></li><li dir="rtl"><p dir="rtl"><strong>جفاف الفم والجلد</strong></p></li><li dir="rtl"><p dir="rtl"><strong>جفاف العين</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التعرق</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الشعور بالضعف والإرهاق</strong></p></li><li dir="rtl"><p dir="rtl"><strong>القلق</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الاكتئاب</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التفكير غير الطبيعي</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الربو</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التهاب الرئتين</strong></p></li><li dir="rtl"><p dir="rtl"><strong>اضطراب الرئتين</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم الظهر</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم الرقبة</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم العظام</strong></p></li><li dir="rtl"><p dir="rtl"><strong>حب الشباب</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تشنجات الساقين</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>الآثار الجانبية غير الشائعة عند استخدام هيرسيبتين: قد تؤثر على 1 من كل 100 أشخاص</strong></p><ul><li dir="rtl"><p dir="RTL"><strong>&nbsp; الصمم</strong></p></li><li dir="rtl"><p dir="RTL"><strong>&nbsp;طفح مصحوب بزوائد جلدية</strong></p></li><li dir="rtl"><p dir="RTL"><strong>ضيق تنفس</strong></p></li><li dir="rtl"><p dir="RTL"><strong>التهاب و ندوب الرئة</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>الآثار الجانبية النادرة عند استخدام هيرسيبتين: قد تؤثر على 1 من كل 1000 أشخاص</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>اليرقان</strong></p></li><li dir="rtl"><p dir="rtl"><strong>رد فعل تحسسي</strong></p></li></ul><p><br />&nbsp;</p><p dir="rtl"><strong>آثار جانبية أخرى تم الإبلاغ عنها عند استخدام هيرسيبتين: لا يمكن التنبؤ بتكرارها بواسطة البيانات المتاحة</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>ضعف او تجلط دم غير طبيعي.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ردود الفعل التأقية</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ارتفاع مستويات البوتاسيوم في الدم</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تورم المخ</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تورم أو نزيف في مؤخرة العين</strong></p></li><li dir="rtl"><p dir="rtl"><strong>صدمة قلبية</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تورم بطانة القلب</strong></p></li><li dir="rtl"><p dir="rtl"><strong>بطء معدل ضربات القلب</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ضربات قلب غير طبيعية</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ضيق في التنفس</strong></p></li><li dir="rtl"><p dir="rtl"><strong>توقف التنفس</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تراكم حاد في السوائل داخل الرئتين</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ضيق حاد في الشعب الهوائية</strong></p></li><li dir="rtl"><p dir="rtl"><strong>انخفاض غير طبيعي في مستوى الاكسجين في الدم.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>صعوبة في التنفس أثناء الاستلقاء</strong></p></li><li dir="rtl"><p dir="rtl"><strong>فشل / تلف الكبد</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تورم الوجه، الشفتين والحلق</strong></p></li><li dir="rtl"><p dir="rtl"><strong>فشل كلوي</strong></p></li><li dir="rtl"><p dir="rtl"><strong>انخفاض غير طبيعي في مستوى السائل حول الجنين داخل الرحم</strong></p></li><li dir="rtl"><p dir="rtl"><strong>فشل تكون رئة الجنين داخل الرحم</strong></p></li><li dir="rtl"><p dir="rtl"><strong>نمو غير طبيعي للكلى لدى الجنين داخل الرحم</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>قد تكون بعض الآثار الجانبية التي تشعر بها بسبب إصابتك بسرطان الثدي. إذا كنت تتلقى العلاج بالهيرسيبتين بالاشتراك مع العلاج الكيميائي، فإن بعض هذه الآثار الجانبية قد يكون أيضا ناتجاً عن العلاج الكيميائي.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>إذا ظهرت لديك أي آثار جانبية، يرجى مراجعة طبيبك أو الصيدلي أو الممرضة.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>التبليغ عن الآثار الجانبية</strong></p><p dir="rtl"><strong>إن تعرضت لأية آثار جانبية، تحدث مع طبيبك أو الصيدلي. ويشمل ذلك أية آثار جانبية غير مدرجة في هذه النشرة. عن طريق الإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>احتفظ بهذا الدواء بعيدًا عن متناول الأطفال.</strong></p><p dir="rtl"><strong>لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية وعلى ملصق القارورة بعد كلمة EXP. ويشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</strong></p><p dir="rtl"><strong>يحفظ في الثلاجة (من 2 إلى 8 درجة مئوية).</strong></p><p dir="rtl"><strong>تحفظ القارورة في عبوتها الخارجية لحمايتها من الضوء.</strong></p><p dir="rtl"><strong>لا تجمد الدواء.</strong></p><p dir="rtl"><strong>يجب استخدام المحلول فورًا بعد فتح القارورة.</strong></p><p dir="rtl"><strong>لا تستخدم هذا الدواء إذا لاحظت وجود شوائب أو تغير في اللون قبل إعطاء الجرعة.</strong></p><p dir="rtl"><strong>لا تتخلص من هذا الدواء من خلال شبكة الصرف الصحي أو مع النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. تساعد هذه الإجراءات على حماية البيئة.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>يحتوي هيرسيبتين على:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>المادة الفعالة هي تراستوزوماب. قارورة واحدة سعة 5 مل تحتوي على 600 ملجم من التراستوزوماب.</strong></p></li></ul><p><strong>المكونات الأخرى هي هيالورونيداز البشري المؤتلف (rHuPH20)، ال-هستيدين، ال-هستيدين هيدروكلوريد أحادي الهيدرات، ألفا ترهالوز ثنائي الهيدرات، ال - ميثيونين، بوليسوربات 20، ماء للحقن.</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>شكل محلول هيرسيبتين ومحتويات العبوة</strong></p><p dir="rtl"><strong>هيرسيبتين هو محلول للحقن يتم توفيره في قوارير زجاجية ذات غطاء من مطاط البوتيل وتحتوي على 5 مل (600 ملجم) من تراستوزوماب. المحلول في الداخل شفاف وبراق وعديم اللون ومائل للاصفرار.</strong></p><p dir="rtl"><strong>تحتوي كل عبوة على قارورة واحدة.</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>شركة ف. هوفمان لا روش المحدودة،</strong></p><p dir="rtl"><strong>142 جرينزاهاشتراس</strong></p><p dir="rtl"><strong>سي إتش &ndash; 4070 بازل</strong></p><p dir="rtl"><strong>&nbsp;سويسرا.</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ يناير 2022





للإبلاغ عن أي آثار جانبية:

المملكة العربية السعودية:
-	المركز الوطني للتيقظ والسلامة الدوائية
o	فاكس: 7662-205-11-966+
o	مركز اتصالات الهيئة العامة للغذاء والدواء: 19999
o	بريد الكتروني: npc.drug@sfda.gov.sa
o	الموقع الإلكتروني: www.sfda.gov.sa/npc

دول مجلس التعاون الخليجي الأخرى:
-	يرجى التواصل مع الهيئة المعنية ذات الصلة

مجلس وزارات الصحة العربية
هذا المنتج دوائي
-	قد تؤثر المنتجات الدوائية على صحتك، ويعد استهلاكه بخلاف الطريقة المحددة أمرًا خطيرًا.
-	اتبع وصفة الطبيب وطريقة الاستخدام وتعليمات الصيدلي الذي باع لك هذا الدواء بدقة.
-	الطبيب والصيدلي خبراء في المنتجات الدوائية وفوائدها ومخاطرها.
-	لا تقطع فترة العلاج المحددة لك من تلقاء نفسك.
-	لا تكرر استخدام نفس الوصفة الطبية دون استشارة طبيبك.
-	احتفظ بجميع المنتجات الدوائية بعيدًا عن متناول الأطفال.


	مجلس وزارات الصحة العربية
اتحاد الصيادلة العرب

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Herceptin 600 mg solution for injection in vial

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One vial of 5 mL contains 600 mg of trastuzumab, a humanised IgG1 monoclonal antibody produced by mammalian (Chinese hamster ovary) cell suspension culture and purified by affinity and ion exchange chromatography including specific viral inactivation and removal procedures.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection

Clear to opalescent solution, colourless to yellowish.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Breast cancer</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Metastatic breast cancer</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC):</strong></p><p>&nbsp;</p><p dir="ltr"><strong>- as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>- in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>- in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>- in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Early breast cancer</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>- following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see section 5.1).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>- following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>- in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.</strong></p><p dir="ltr"><strong>- in combination with neoadjuvant chemotherapy followed by adjuvant Herceptin therapy, for locally advanced (including inflammatory) disease or tumours &gt; 2 cm in diameter (see sections 4.4 and 5.1).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Herceptin should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay (see sections 4.4 and 5.1).</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>HER2 testing is mandatory prior to initiation of therapy (see sections 4.4 and 5.1). Herceptin treatment should only be initiated by a physician experienced in the administration of cytotoxic chemotherapy (see section 4.4), and should be administered by a healthcare professional only.<br />It is important to check the product labels to ensure that the correct formulation (intravenous or subcutaneous fixed dose) is being administered to the patient, as prescribed. Herceptin subcutaneous formulation is not intended for intravenous administration and should be administered via a subcutaneous injection only.<br />Switching treatment between Herceptin intravenous and Herceptin subcutaneous formulations and vice versa, using the three-weekly (q3w) dosing regimen, was investigated in study MO22982 (see section 4.8).<br />In order to prevent medication errors it is important to check the vial labels to ensure that the drug being prepared and administered is Herceptin (trastuzumab) and not another trastuzumab-containing product (e.g. trastuzumab emtansine or trastuzumab deruxtecan).<br />Posology<br />The recommended dose for Herceptin subcutaneous formulation is 600 mg irrespective of the patient&rsquo;s body weight. No loading dose is required. This dose should be administered subcutaneously over 2-5 minutes every three weeks.<br />In the pivotal trial (BO22227) Herceptin subcutaneous formulation was administered in the neoadjuvant/adjuvant setting in patients with early breast cancer. The preoperative chemotherapy regimen consisted of docetaxel (75 mg/m&sup2;) followed by FEC (5FU, epirubicin and cyclophosphamide) at a standard dose.</strong><br />&nbsp;</p><p dir="ltr"><strong>See section 5.1 for chemotherapy combination dosing.</strong><br />&nbsp;</p><p dir="ltr"><strong>Duration of treatment<br />Patients with MBC should be treated with Herceptin until progression of disease. Patients with EBC should be treated with Herceptin for 1 year or until disease recurrence, whichever occurs first; extending treatment in EBC beyond one year is not recommended (see section 5.1).</strong><br />&nbsp;</p><p dir="ltr"><strong>Dose reduction<br />No reductions in the dose of Herceptin were made during clinical trials. Patients may continue therapy during periods of reversible, chemotherapy-induced myelosuppression butthey should be monitored carefully for complications of neutropenia during this time. Refer to the Summary of Product</strong></p><p>&nbsp;</p><p><strong>Characteristics (SmPC) for paclitaxel, docetaxel or aromatase inhibitor for information on dose reduction or delays.</strong></p><p><br /><strong>If left ventricular ejection fraction (LVEF) percentage drops &ge; 10 points from baseline AND to below 50 %, treatment should be suspended and a repeat LVEF assessment performed within approximately 3 weeks. If LVEF has not improved, or has declined further, or if symptomatic congestive heart failure (CHF) has developed, discontinuation of Herceptin should be strongly considered, unless the benefits for the individual patient are deemed to outweigh the risks. All such patients should be referred for assessment by a cardiologist and followed up.</strong></p><p><strong>Missed doses<br />If the patient misses a dose of Herceptin subcutaneous formulation, it is recommended to administer the next 600 mg dose (i.e. the missed dose) as soon as possible. The interval between consecutive Herceptin subcutaneous formulation administrations should not be less than three weeks.</strong></p><p><strong>Special populations<br />Dedicated pharmacokinetic studies in the elderly and those with renal or hepatic impairment have not been carried out. In a population pharmacokinetic analysis, age and renal impairment were not shown to affect trastuzumab disposition.</strong></p><p><strong>Paediatric population<br />There is no relevant use of Herceptin in the paediatric population.</strong></p><p><strong>Method of administration<br />The 600 mg dose should be administered as a subcutaneous injection only over 2-5 minutes every three weeks. The injection site should be alternated between the left and right thigh. New injections should be given at least 2.5 cm from the old site and never into areas where the skin is red, bruised, tender, or hard. During the treatment course with Herceptin subcutaneous formulation other medicinal products for subcutaneous administration should preferably be injected at different sites. Patients should be observed for 30 minutes after the first injection and for 15 minutes after subsequent injections for signs or symptoms of administration-related reactions (see sections 4.4 and 4.8).</strong></p><p><strong>For instructions on use and handling of Herceptin subcutaneous formulation refer to section 6.6.</strong><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to trastuzumab, murine proteins, hyaluronidase or to any of the other excipients listed in section 6.1.
∙	Severe dyspnoea at rest due to complications of advanced malignancy or requiring supplementary oxygen therapy.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Traceability</strong></p><p dir="ltr"><br /><strong>In order to improve the traceability of biological medicinal products, the trade name and the batch number of the administered product should be clearly recorded.<br />HER2 testing must be performed in a specialised laboratory which can ensure adequate validation of the testing procedures (see section 5.1).</strong></p><p dir="ltr"><strong>Currently no data from clinical trials are available on re-treatment of patients with previous exposure to Herceptin in the adjuvant setting.</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Cardiac dysfunction</strong></p><p dir="ltr"><br /><strong>General considerations</strong></p><p dir="ltr"><br /><strong>Patients treated with Herceptin are at increased risk for developing CHF (New York Heart Association [NYHA] Class II-IV) or asymptomatic cardiac dysfunction. These events have been observed in patients receiving Herceptin therapy alone or in combination with paclitaxel or docetaxel, particularly following anthracycline (doxorubicin or epirubicin)&ndash;containing chemotherapy. These may be moderate to severe and have been associated with death (see section 4.8). In addition, caution should be exercised in treating patients with increased cardiac risk, e.g. hypertension, documented coronary artery disease, CHF, LVEF of &lt;55%, older age.</strong><br />&nbsp;</p><p dir="ltr"><strong>All candidates for treatment with Herceptin, but especially those with prior anthracycline and cyclophosphamide exposure, should undergo baseline cardiac assessment including history and physical examination and electrocardiogram (ECG), echocardiogram, and/or multigated acquisition (MUGA) scan or magnetic resonance imaging. Monitoring may help to identify patients who develop cardiac dysfunction. Cardiac assessments, as performed at baseline, should be repeated every 3 months during treatment and every 6 months following discontinuation of treatment until 24 months from the last administration of Herceptin. A careful risk-benefit assessment should be made before deciding to treat with Herceptin.</strong><br />&nbsp;</p><p dir="ltr"><strong>Trastuzumab may persist in the circulation for up to 7 months after stopping Herceptin treatment based on population pharmacokinetic analysis of all available data (see section 5.2). Patients who receive anthracyclines after stopping Herceptin may possibly be at increased risk of cardiac dysfunction. If possible, physicians should avoid anthracycline-based therapy for up to 7 months after stopping Herceptin. If anthracyclines are used, the patient&rsquo;s cardiac function should be monitored carefully.</strong><br />&nbsp;</p><p dir="ltr"><strong>Formal cardiological assessment should be considered in patients in whom there are cardiovascular concerns following baseline screening. In all patients cardiac function should be monitored during treatment (e.g. every 12 weeks). Monitoring may help to identify patients who develop cardiac dysfunction. Patients who develop asymptomatic cardiac dysfunction may benefit from more frequent monitoring (e.g. every 6-8 weeks). If patients have a continued decrease in left ventricular function, but remain asymptomatic, the physician should consider discontinuing therapy if no clinical benefit of Herceptin therapy has been seen.</strong><br />&nbsp;</p><p dir="ltr"><strong>The safety of continuation or resumption of Herceptin in patients who experience cardiac dysfunction has not been prospectively studied. If LVEF percentage drops &ge; 10 points from baseline AND to below 50%, treatment should be suspended and a repeat LVEF assessment performed within approximately 3 weeks. If LVEF has not improved, or declined further, or symptomatic CHF has developed, discontinuation of Herceptin should be strongly considered, unless the benefits for the individual patient are deemed to outweigh the risks. All such patients should be referred for assessment by a cardiologist and followed up.</strong><br />&nbsp;</p><p dir="ltr"><strong>If symptomatic cardiac failure develops during Herceptin therapy, it should be treated with standard medicinal products for CHF. Most patients who developed CHF or asymptomatic cardiac dysfunction in pivotal trials improved with standard CHF treatment consisting of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) and a beta-blocker. The majority of patients with cardiac symptoms and evidence of a clinical benefit of Herceptin treatment continued on therapy without additional clinical cardiac events.</strong><br />&nbsp;</p><p dir="ltr"><strong>Metastatic breast cancer</strong></p><p dir="ltr"><strong>Herceptin and anthracyclines should not be given concurrently in combination in the MBC setting.</strong><br />&nbsp;</p><p dir="ltr"><strong>Patients with MBC who have previously received anthracyclines are also at risk of cardiac dysfunction with Herceptin treatment, although the risk is lower than with concurrent use of Herceptin and anthracyclines.</strong><br />&nbsp;</p><p dir="ltr"><strong>Early breast cancer<br />For patients with EBC, cardiac assessments, as performed at baseline, should be repeated every 3 months during treatment and every 6 months following discontinuation of treatment until 24 months from the last administration of Herceptin. In patients who receive anthracycline-containing chemotherapy further monitoring is recommended, and should occur yearly up to 5 years from the last administration of Herceptin, or longer if a continuous decrease of LVEF is observed.</strong><br />&nbsp;</p><p dir="ltr"><strong>Patients with history of myocardial infarction (MI), angina pectoris requiring medical treatment, history of or existing CHF (NYHA Class II &ndash;IV), LVEF of &lt; 55%, other cardiomyopathy, cardiac arrhythmia requiring medical treatment, clinically significant cardiac valvular disease, poorly controlled hypertension (hypertension controlled by standard medical treatment eligible), and hemodynamic effective pericardial effusion were excluded from adjuvant and neoadjuvant EBC pivotal trials with Herceptin and therefore treatment cannot be recommended in such patients.</strong><br />&nbsp;</p><p dir="ltr"><strong>Adjuvant treatment</strong><br />&nbsp;</p><p dir="ltr"><strong>Herceptin and anthracyclines should not be given concurrently in the adjuvant treatment setting.</strong><br />&nbsp;</p><p dir="ltr"><strong>In patients with EBC an increase in the incidence of symptomatic and asymptomatic cardiac events was observed when Herceptin (intravenous formulation) was administered after anthracycline-containing chemotherapy compared to administration with a non-anthracycline regimen of docetaxel and carboplatin and was more marked when Herceptin (intravenous formulation) was administered concurrently with taxanes than when administered sequentially to taxanes. Regardless of the regimen used, most symptomatic cardiac events occurred within the first 18 months. In one of the 3 pivotal studies conducted in which a median follow-up of 5.5 years was available (BCIRG006) a continuous increase in the cumulative rate of symptomatic cardiac or LVEF events was observed (up to 2.37 %) in patients who were administered Herceptin concurrently with a taxane following anthracycline therapy, compared to approximately 1 % in the two comparator arms (anthracycline plus cyclophosphamide followed by taxane and taxane, carboplatin and Herceptin).</strong><br />&nbsp;</p><p dir="ltr"><strong>Risk factors for a cardiac event identified in four large adjuvant studies included advanced age (&gt; 50 years), low LVEF (&lt;55%) at baseline, prior to or following the initiation of paclitaxel treatment, decline in LVEF by 10-15 points, and prior or concurrent use of anti-hypertensive medicinal products. In patients receiving Herceptin after completion of adjuvant chemotherapy, the risk of cardiac dysfunction was associated with a higher cumulative dose of anthracycline given prior to initiation of Herceptin and a body mass index (BMI) &gt;25 kg/m2.</strong><br />&nbsp;</p><p dir="ltr"><strong>Neoadjuvant-adjuvant treatment<br />In patients with EBC eligible for neoadjuvant-adjuvant treatment, Herceptin should be used concurrently with anthracyclines only in chemotherapy-naive patients and only with low-dose anthracycline regimens, i.e., with maximum cumulative doses of doxorubicin 180 mg/m2 or epirubicin 360 mg/m2.</strong><br />&nbsp;</p><p dir="ltr"><strong>If patients have been treated concurrently with a full course of low-dose anthracyclines and Herceptin in the neoadjuvant setting, no additional cytotoxic chemotherapy should be given after surgery. In&nbsp;other situations, the decision on the need for additional cytotoxic chemotherapy is determined based on individual factors.</strong><br />&nbsp;</p><p dir="ltr"><strong>Experience of concurrent administration of trastuzumab with low dose anthracycline regimens is currently limited to two trials (MO16432 and BO22227).</strong><br />&nbsp;</p><p dir="ltr"><strong>In the pivotal trial MO16432, Herceptin was administered concurrently with neoadjuvant chemotherapy containing three cycles of doxorubicin (cumulative dose 180 mg/m2) . The incidence of symptomatic cardiac dysfunction was 1.7% in the Herceptin arm .</strong><br />&nbsp;</p><p dir="ltr"><strong>In the pivotal trial BO22227, Herceptin was administered concurrently with neoadjuvant chemotherapy that contained four cycles of epirubicin (cumulative dose 300 mg/m2); at a median follow-up exceeding 70 months, the incidence of cardiac failure/congestive cardiac failure was 0.3% in the Herceptin intravenous arm and 0.7% in the Herceptin subcutaneous arm. In patients with lower body weights (&lt;59 kg, the lowest body weight quartile) the fixed dose used in the Herceptin subcutaneous arm was not associated with an increased risk of cardiac events or significant drop in LVEF.</strong><br />&nbsp;</p><p dir="ltr"><strong>Clinical experience is limited in patients above 65 years of age.</strong><br />&nbsp;</p><p dir="ltr"><strong>Administration-related reactions</strong><br />&nbsp;</p><p dir="ltr"><strong>Administration-related reactions (ARRs) are known to occur with Herceptin subcutaneous formulation. Pre-medication may be used to reduce risk of occurrence of ARRs.</strong><br />&nbsp;</p><p dir="ltr"><strong>Although serious ARRs, including dyspnoea, hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen saturation and respiratory distress, were not reported in the clinical trial with the Herceptin subcutaneous formulation, caution should be exercised as these have been associated with the intravenous formulation. Patients should be observed for ARRs for 30 minutes after the first injection and for 15 minutes after subsequent injections. ARRs considered mild in severity can be treated with an analgesic/antipyretic such as meperidine or paracetamol, or an antihistamine such as diphenhydramine. Serious reactions to intravenous Herceptin have been treated successfully with supportive therapy such as oxygen, beta-agonists, and corticosteroids. In rare cases, these reactions were associated with a clinical course culminating in a fatal outcome. Patients experiencing dyspnoea at rest due to complications of advanced malignancy and comorbidities may be at increased risk of a fatal ARR. Therefore, these patients should not be treated with Herceptin (see section 4.3).</strong><br />&nbsp;</p><p dir="ltr"><strong>Pulmonary events<br />Caution is recommended with Herceptin subcutaneous formulation as severe pulmonary events have been reported with the use of the intravenous formulation in the post-marketing setting (see section 4.8). These events have occasionally been fatal and may occur as part of an infusion-related reaction or with delayed onset. In addition, cases of interstitial lung disease including lung infiltrates, acute respiratory distress syndrome, pneumonia, pneumonitis, pleural effusion, respiratory distress, acute pulmonary oedema and respiratory insufficiency have been reported. Risk factors associated with interstitial lung disease include prior or concomitant therapy with other anti-neoplastic therapies known to be associated with it such as taxanes, gemcitabine, vinorelbine and radiation therapy. Patients experiencing dyspnoea at rest due to complications of advanced malignancy and comorbidities may be at increased risk of pulmonary events. Therefore, these patients should not be treated with Herceptin (see section 4.3). Caution should be exercised for pneumonitis, especially in patients being treated concomitantly with taxanes.</strong><br />&nbsp;</p><p dir="ltr"><strong>Sodium<br />Herceptin contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodium-free.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>No formal drug interaction studies have been performed. Clinically significant interactions between Herceptin and the concomitant medicinal products used in clinical trials have not been observed.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Effect of trastuzumab on the pharmacokinetics of other antineoplastic agents</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pharmacokinetic data from studies BO15935 and M77004 in women with HER2-positive MBC suggested that exposure to paclitaxel and doxorubicin (and their major metabolites 6-&alpha; hydroxyl-paclitaxel, POH, and doxorubicinol, DOL) was not altered in the presence of trastuzumab (8&nbsp;mg/kg or 4&nbsp;mg/kg IV loading dose followed by 6&nbsp;mg/kg q3w or 2&nbsp;mg/kg q1w IV, respectively).</strong></p><p dir="ltr"><strong>However, trastuzumab may elevate the overall exposure of one doxorubicin metabolite, (7-deoxy-13 dihydro-doxorubicinone, D7D). The bioactivity of D7D and the clinical impact of the elevation of this metabolite was unclear.&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Data from study JP16003, a single-arm study of Herceptin (4 mg/kg IV loading dose and 2 mg/kg IV weekly) and docetaxel (60 mg/m2 IV) in Japanese women with HER2- positive MBC, suggested that concomitant administration of Herceptin had no effect on the single dose pharmacokinetics of docetaxel. Study JP19959 was a substudy of BO18255 (ToGA) performed in male and female Japanese patients with advanced gastric cancer to study the pharmacokinetics of capecitabine and cisplatin when used with or without Herceptin. The results of this substudy suggested that the exposure to the bioactive metabolites (e.g. 5-FU) of capecitabine was not affected by concurrent use of cisplatin or by concurrent use of cisplatin plus Herceptin. However, capecitabine itself showed higher concentrations and a longer half-life when combined with Herceptin. The data also suggested that the pharmacokinetics of cisplatin were not affected by concurrent use of capecitabine or by concurrent use of capecitabine plus Herceptin.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pharmacokinetic data from Study H4613g/GO01305 in patients with metastatic or locally advanced inoperable HER2-positive cancer suggested that trastuzumab had no impact on the PK of carboplatin.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Effect of antineoplastic agents on trastuzumab pharmacokinetics</strong></p><p>&nbsp;</p><p dir="ltr"><strong>By comparison of simulated serum trastuzumab concentrations after Herceptin monotherapy (4 mg/kg loading/2 mg/kg q1w IV) and observed serum concentrations in Japanese women with HER2- positive MBC (study JP16003) no evidence of a PK effect of concurrent administration of docetaxel on the pharmacokinetics of trastuzumab was found.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Comparison of PK results from two Phase II studies (BO15935 and M77004) and one Phase III study (H0648g) in which patients were treated concomitantly with Herceptin and paclitaxel and two Phase II studies in which Herceptin was administered as monotherapy (W016229 and MO16982), in women with HER2-positive MBC indicates that individual and mean trastuzumab trough serum concentrations varied within and across studies but there was no clear effect of the concomitant administration of paclitaxel on the pharmacokinetics of trastuzumab. Comparison of trastuzumab PK data from Study M77004 in which women with HER2-positive MBC were treated concomitantly with Herceptin, paclitaxel and doxorubicin to trastuzumab PK data in studies where Herceptin was administered as monotherapy (H0649g) or in combination with anthracycline plus cyclophosphamide or paclitaxel (Study H0648g), suggested no effect of doxorubicin and paclitaxel on the pharmacokinetics of trastuzumab.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pharmacokinetic data from Study H4613g/GO01305 suggested that carboplatin had no impact on the PK of trastuzumab.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The administration of concomitant anastrozole did not appear to influence the pharmacokinetics of trastuzumab.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Women of childbearing potential / Contraception</strong><br />&nbsp;</p><p dir="ltr"><strong>Women of childbearing potential should be advised to use effective contraception during treatment with Herceptin and for 7 months after treatment has concluded (see section 5.2).</strong><br />&nbsp;</p><p dir="ltr"><strong>Pregnancy</strong><br />&nbsp;</p><p dir="ltr"><strong>Reproduction studies have been conducted in Cynomolgus monkeys at doses up to 25 times that of the weekly human maintenance dose of 2 mg/kg Herceptin intravenous formulation and have revealed no evidence of impaired fertility or harm to the fetus. Placental transfer of trastuzumab during the early (days 20-50 of gestation) and late (days 120-150 of gestation) fetal development period was observed. It is not known whether Herceptin can affect reproductive capacity. As animal reproduction studies are not always predictive of human response, Herceptin should be avoided during pregnancy unless the potential benefit for the mother outweighs the potential risk to the fetus.</strong><br />&nbsp;</p><p dir="ltr"><strong>In the post-marketing setting, cases of fetal renal growth and/or function impairment in association with oligohydramnios, some associated with fatal pulmonary hypoplasia of the fetus, have been reported in pregnant women receiving Herceptin. Women who become pregnant should be advised of the possibility of harm to the fetus. If a pregnant woman is treated with Herceptin, or if a patient becomes pregnant while receiving Herceptin or within 7 months following last dose of Herceptin, close monitoring by a multidisciplinary team is desirable.</strong><br />&nbsp;</p><p dir="ltr"><strong>Breast-feeding<br />A study conducted in Cynomolgus monkeys at doses 25 times that of the weekly human maintenance dose of 2 mg/kg Herceptin intravenous formulation from days 120 to 150 of pregnancy demonstrated that trastuzumab is secreted in the milk postpartum. The exposure to trastuzumab in utero and the presence of trastuzumab in the serum of infant monkeys was not associated with any adverse effects on their growth or development from birth to 1 month of age. It is not known whether trastuzumab is secreted in human milk. As human IgG1 is secreted into human milk, and the potential for harm to the infant is unknown, women should not breast-feed during Herceptin therapy and for 7 months after the last dose.</strong><br />&nbsp;</p><p dir="ltr"><strong>Fertility<br />There is no fertility data available.</strong><strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p dir="ltr"><strong>Herceptin has a minor influence on the ability to drive or use machines (see section 4.8). Dizziness and somnolence may occur during treatment with Herceptin (see section 4.8). Patients experiencing administration-related symptoms (see section 4.4) should be advised not to drive and use machines until symptoms abate.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Summary of the safety profile</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Amongst the most serious and/or common adverse reactions reported in Herceptin usage (intravenous and subcutaneous formulations) to date are cardiac dysfunction, administration-related reactions, haematotoxicity (in particular neutropenia), infections and pulmonary adverse reactions.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The safety profile of Herceptin subcutaneous formulation (evaluated in 298 and 297 patients treated with the intravenous and subcutaneous formulations respectively) from the pivotal trial in EBC was overall similar to the known safety profile of the intravenous formulation.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Severe adverse events (defined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE grade &ge;3) version 3.0) were equally distributed between both Herceptin formulations (52.3&nbsp;% versus 53.5&nbsp;% in the intravenous formulation versus subcutaneous formulation respectively).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Some adverse events / reactions were reported with a higher frequency for the subcutaneous formulation:</strong></p><p dir="ltr"><strong>∙ Serious adverse events (most of which were identified because of in-patient hospitalisation or prolongation of existing hospitalisation): 14.1&nbsp;% for the intravenous formulation versus 21.5&nbsp;% for the subcutaneous formulation. The difference in serious adverse event rates between formulations was mainly due to infections with or without neutropenia (4.4&nbsp;% versus 8.1&nbsp;%) and cardiac disorders (0.7&nbsp;% versus 1.7&nbsp;%);</strong></p><p dir="ltr"><strong>∙ Post-operative wound infections (severe and/or serious): 1.7&nbsp; % versus 3.0&nbsp; % for the intravenous formulation versus subcutaneous formulation, respectively;</strong></p><p dir="ltr"><strong>∙ Administration-related reactions: 37.2&nbsp;% versus 47.8&nbsp;% for the intravenous formulation versus subcutaneous formulation, respectively during the treatment phase;</strong></p><p dir="ltr"><strong>∙ Hypertension: 4.7&nbsp;% versus 9.8&nbsp;% for the intravenous formulation versus subcutaneous formulation respectively.&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Tabulated list of adverse reactions with the intravenous formulation</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In this section, the following categories of frequency have been used: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Presented in Table 1 are adverse reactions that have been reported in association with the use of intravenous Herceptin alone or in combination with chemotherapy in pivotal clinical trials and in the post-marketing setting.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>All the terms included are based on the highest percentage seen in pivotal clinical trials.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 1: Undesirable effects reported with intravenous Herceptin monotherapy or in combination with chemotherapy in pivotal clinical trials (N = 8386) and in post-marketing</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:790px"><thead><tr><td style="vertical-align:top; width:313px"><p><strong>System organ class</strong></p></td><td style="vertical-align:top; width:357px"><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top; width:118px"><p><strong>Frequency </strong></p></td></tr></thead><tbody><tr><td rowspan="11" style="vertical-align:top; width:313px"><p>Infections and infestations</p></td><td style="vertical-align:top; width:357px"><p>Infection</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Nasopharyngitis</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Neutropenic sepsis</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Cystitis</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Influenza</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Sinusitis</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Skin infection</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Rhinitis</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Upper respiratory tract infection</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Urinary tract infection</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Pharyngitis</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:313px"><p>Neoplasms benign, malignant and unspecified (incl. Cysts and polyps)</p></td><td style="vertical-align:top; width:357px"><p>Malignant neoplasm progression</p></td><td style="vertical-align:top; width:118px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Neoplasm progression</p></td><td style="vertical-align:top; width:118px"><p>Not known</p></td></tr><tr><td rowspan="7" style="vertical-align:top; width:313px"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top; width:357px"><p>Febrile neutropenia</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Anaemia</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Neutropenia</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>White blood cell count decreased/leukopenia</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Thrombocytopenia</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Hypoprothrombinaemia</p></td><td style="vertical-align:top; width:118px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Immune thrombocytopenia</p></td><td style="vertical-align:top; width:118px"><p>Not known</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:313px"><p>Immune system disorders</p></td><td style="vertical-align:top; width:357px"><p>Hypersensitivity</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p><sup>+</sup>Anaphylactic reaction</p></td><td style="vertical-align:top; width:118px"><p>Rare</p></td></tr><tr><td style="vertical-align:top; width:357px"><p><sup>+</sup>Anaphylactic shock</p></td><td style="vertical-align:top; width:118px"><p>Rare</p></td></tr><tr><td rowspan="4" style="vertical-align:top; width:313px"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top; width:357px"><p>Weight decreased/Weight loss</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Anorexia</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Tumour lysis syndrome</p></td><td style="vertical-align:top; width:118px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Hyperkalaemia</p></td><td style="vertical-align:top; width:118px"><p>Not known</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:313px"><p>Psychiatric disorders</p></td><td style="vertical-align:top; width:357px"><p>Insomnia</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Anxiety</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Depression</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td rowspan="8" style="vertical-align:top; width:313px"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:357px"><p><sup>1</sup>Tremor</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Dizziness</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Headache</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Paraesthesia</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Dysgeusia</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Peripheral neuropathy</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Hypertonia</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Somnolence</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td rowspan="5" style="vertical-align:top; width:313px"><p>Eye disorders</p></td><td style="vertical-align:top; width:357px"><p>Conjunctivitis</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Lacrimation increased</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Dry eye</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Papilloedema</p></td><td style="vertical-align:top; width:118px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:357px"><p>Retinal haemorrhage</p></td><td style="vertical-align:top; width:118px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:313px"><p>Ear and labyrinth disorders</p><p>&nbsp;</p></td><td style="vertical-align:top; width:357px"><p>Deafness</p></td><td style="vertical-align:top; width:118px"><p>Uncommon</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:791px"><tbody><tr><td rowspan="9" style="vertical-align:top; width:313px"><p>Cardiac disorders</p></td><td style="vertical-align:top; width:358px"><p><sup>1</sup> Blood pressure decreased</p></td><td style="vertical-align:top; width:117px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:358px"><p><sup>1</sup> Blood pressure increased</p></td><td style="vertical-align:top; width:117px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:358px"><p><sup>1</sup> Heart beat irregular</p></td><td style="vertical-align:top; width:117px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:358px"><p><sup>1</sup>Cardiac flutter</p></td><td style="vertical-align:top; width:117px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:358px"><p>Ejection fraction decreased*</p></td><td style="vertical-align:top; width:117px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:358px"><p><sup>+</sup>Cardiac failure (congestive)</p></td><td style="vertical-align:top; width:117px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:358px"><p><sup>+1</sup>Supraventricular tachyarrhythmia</p></td><td style="vertical-align:top; width:117px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:358px"><p>Cardiomyopathy</p></td><td style="vertical-align:top; width:117px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:358px"><p><sup>1</sup>Palpitation</p></td><td style="vertical-align:top; width:117px"><p>Common</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:313px"><p>&nbsp;</p></td><td style="vertical-align:top; width:358px"><p>Pericardial effusion</p></td><td style="vertical-align:top; width:117px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:358px"><p>Cardiogenic shock</p></td><td style="vertical-align:top; width:117px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:358px"><p>Gallop rhythm present</p></td><td style="vertical-align:top; width:117px"><p>Not known</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:313px"><p>Vascular disorders</p></td><td style="vertical-align:top; width:358px"><p>Hot flush</p></td><td style="vertical-align:top; width:117px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:358px"><p><sup>+1 </sup>Hypotension</p></td><td style="vertical-align:top; width:117px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:358px"><p>Vasodilatation</p></td><td style="vertical-align:top; width:117px"><p>Common</p></td></tr><tr><td rowspan="23" style="vertical-align:top; width:313px"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top; width:358px"><p><sup>+</sup>Dyspnoea</p></td><td style="vertical-align:top; width:117px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:358px"><p>Cough</p></td><td style="vertical-align:top; width:117px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:358px"><p>Epistaxis</p></td><td style="vertical-align:top; width:117px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:358px"><p>Rhinorrhoea</p></td><td style="vertical-align:top; width:117px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:358px"><p><sup>+</sup>Pneumonia</p></td><td style="vertical-align:top; width:117px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:358px"><p>Asthma</p></td><td style="vertical-align:top; width:117px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:358px"><p>Lung disorder</p></td><td style="vertical-align:top; width:117px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:358px"><p><sup>+</sup>Pleural effusion</p></td><td style="vertical-align:top; width:117px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:358px"><p><sup>+1</sup>Wheezing</p></td><td style="vertical-align:top; width:117px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:358px"><p>Pneumonitis</p></td><td style="vertical-align:top; width:117px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:358px"><p><sup>+</sup>Pulmonary fibrosis</p></td><td style="vertical-align:top; width:117px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:358px"><p><sup>+</sup>Respiratory distress</p></td><td style="vertical-align:top; width:117px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:358px"><p><sup>+</sup>Respiratory failure</p></td><td style="vertical-align:top; width:117px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:358px"><p><sup>+</sup>Lung infiltration</p></td><td style="vertical-align:top; width:117px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:358px"><p><sup>+</sup>Acute pulmonary oedema</p></td><td style="vertical-align:top; width:117px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:358px"><p><sup>+</sup>Acute respiratory distress syndrome</p></td><td style="vertical-align:top; width:117px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:358px"><p><sup>+</sup>Bronchospasm</p></td><td style="vertical-align:top; width:117px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:358px"><p><sup>+</sup>Hypoxia</p></td><td style="vertical-align:top; width:117px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:358px"><p><sup>+</sup>Oxygen saturation decreased</p></td><td style="vertical-align:top; width:117px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:358px"><p>Laryngeal oedema</p></td><td style="vertical-align:top; width:117px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:358px"><p>Orthopnoea</p></td><td style="vertical-align:top; width:117px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:358px"><p>Pulmonary oedema</p></td><td style="vertical-align:top; width:117px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:358px"><p>Interstitial lung disease</p></td><td style="vertical-align:top; width:117px"><p>Not known</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:793px"><tbody><tr><td rowspan="10" style="vertical-align:top; width:313px"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:359px"><p>Diarrhoea</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Vomiting</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Nausea</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p><sup>1 </sup>Lip swelling</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Abdominal pain</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Dyspepsia</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Constipation</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Stomatitis</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Haemorrhoids</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Dry mouth</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td rowspan="4" style="vertical-align:top; width:313px"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top; width:359px"><p>Hepatocellular Injury</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Hepatitis</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Liver Tenderness</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Jaundice</p></td><td style="vertical-align:top; width:118px"><p>Rare</p></td></tr><tr><td rowspan="16" style="vertical-align:top; width:313px"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:359px"><p>Erythema</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Rash</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p><sup>1 </sup>Swelling face</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Alopecia</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Nail disorder</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Palmar-plantar erythrodysaesthesia syndrome</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Acne</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Dry skin</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Ecchymosis</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Hyperhydrosis</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Maculopapular rash</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Pruritus</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Onychoclasis</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Dermatitis</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Urticaria</p></td><td style="vertical-align:top; width:118px"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Angioedema</p></td><td style="vertical-align:top; width:118px"><p>Not known</p></td></tr><tr><td rowspan="9" style="vertical-align:top; width:313px"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top; width:359px"><p>Arthralgia</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p><sup>1</sup>Muscle tightness</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Myalgia</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Arthritis</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Back pain</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Bone pain</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Muscle spasms</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Neck pain</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Pain in extremity</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td rowspan="4" style="vertical-align:top; width:313px"><p>Renal and urinary disorders</p></td><td style="vertical-align:top; width:359px"><p>Renal disorder</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Glomerulonephritis membranous</p></td><td style="vertical-align:top; width:118px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Glomerulonephropathy</p></td><td style="vertical-align:top; width:118px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:359px"><p>Renal failure</p></td><td style="vertical-align:top; width:118px"><p>Not known</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:794px"><tbody><tr><td rowspan="3" style="vertical-align:top; width:311px"><p>Pregnancy, puerperium and perinatal conditions</p></td><td style="vertical-align:top; width:362px"><p>Oligohydramnios</p></td><td style="vertical-align:top; width:118px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:362px"><p>Renal hypoplasia</p></td><td style="vertical-align:top; width:118px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:362px"><p>Pulmonary hypoplasia</p></td><td style="vertical-align:top; width:118px"><p>Not known</p></td></tr><tr><td style="vertical-align:top; width:311px"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top; width:362px"><p>Breast inflammation/mastitis</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td rowspan="12" style="vertical-align:top; width:311px"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:362px"><p>Asthenia</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:362px"><p>Chest pain</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:362px"><p>Chills</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:362px"><p>Fatigue</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:362px"><p>Influenza-like symptoms</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:362px"><p>Infusion related reaction</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:362px"><p>Pain</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:362px"><p>Pyrexia</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:362px"><p>Mucosal inflammation</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:362px"><p>Peripheral oedema</p></td><td style="vertical-align:top; width:118px"><p>Very common</p></td></tr><tr><td style="vertical-align:top; width:362px"><p>Malaise</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:362px"><p>Oedema</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr><tr><td style="vertical-align:top; width:311px"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top; width:362px"><p>Contusion</p></td><td style="vertical-align:top; width:118px"><p>Common</p></td></tr></tbody></table><p dir="ltr"><strong>+ Denotes adverse reactions that have been reported in association with a fatal outcome.</strong></p><p dir="ltr"><strong>1 Denotes adverse reactions that are reported largely in association with administration-related reactions. Specific percentages for these are not available.</strong></p><p dir="ltr"><strong>* Observed with combination therapy following anthracyclines and combined with taxanes</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Description of selected adverse reactions</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Cardiac dysfunction</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Congestive heart failure (NYHA Class II-IV) is a common adverse reaction to Herceptin. It has been associated with a fatal outcome. Signs and symptoms of cardiac dysfunction such as dyspnoea, orthopnoea, increased cough, pulmonary oedema, S3 gallop, or reduced ventricular ejection fraction, have been observed in patients treated with Herceptin (see section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In 3 pivotal EBC clinical trials of adjuvant intravenous Herceptin given in combination with chemotherapy, the incidence of grade 3/4 cardiac dysfunction (specifically symptomatic congestive heart failure) was similar in patients who were administered chemotherapy alone (ie did not receive Herceptin) and in patients who were administered Herceptin sequentially after a taxane (0.3-0.4&nbsp;%). The rate was highest in patients who were administered Herceptin concurrently with a taxane (2.0&nbsp;%). In the neoadjuvant setting, the experience of concurrent administration of Herceptin and low dose anthracycline regimen is limited (see section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>When Herceptin was administered after completion of adjuvant chemotherapy NYHA Class III-IV heart failure was observed in 0.6 % of patients in the one-year arm after a median follow-up of 12 months. In study BO16348, after a median follow-up of 8 years the incidence of severe CHF (NYHA Class III &amp; IV) in the Herceptin 1 year treatment arm was 0.8 %, and the rate of mild symptomatic and asymptomatic left ventricular dysfunction was 4.6 %.</strong></p><p dir="ltr"><strong>Reversibility of severe CHF (defined as a sequence of at least two consecutive LVEF values &ge;50&nbsp;% after the event) was evident for 71.4 % of Herceptin-treated patients. Reversibility of mild symptomatic and asymptomatic left ventricular dysfunction was demonstrated for 79.5 % of patients. Approximately 17 % of cardiac dysfunction related events occurred after completion of Herceptin.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the pivotal metastatic trials of intravenous Herceptin, the incidence of cardiac dysfunction varied between 9&nbsp;% and 12&nbsp;% when it was combined with paclitaxel compared with 1&nbsp;% &ndash; 4&nbsp;% for paclitaxel alone. For monotherapy, the rate was 6&nbsp;% &ndash; 9&nbsp;%. The highest rate of cardiac dysfunction was seen in patients receiving Herceptin concurrently with anthracycline/cyclophosphamide (27&nbsp;%), and was significantly higher than for anthracycline/cyclophosphamide alone (7&nbsp;% &ndash; 10&nbsp;%). In a subsequent trial with prospective monitoring of cardiac function, the incidence of symptomatic CHF was 2.2&nbsp;% in patients receiving Herceptin and docetaxel, compared with 0&nbsp;% in patients receiving docetaxel alone. Most of the patients (79&nbsp;%) who developed cardiac dysfunction in these trials experienced an improvement after receiving standard treatment for CHF.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Administrationrelated reactions/hypersensitivity</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Administrationrelated reactions (ARRs)/hypersensitivity reactions such as chills and/or fever, dyspnoea, hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen saturation, respiratory distress, rash, nausea, vomiting and headache were seen in Herceptin clinical trials (see section 4.4). The rate of ARRs of all grades varied between studies depending on the indication, the data collection methodology, and whether trastuzumab was given concurrently with chemotherapy or as monotherapy.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Anaphylactoid reactions have been observed in isolated cases.</strong></p><p><br /><br /><br />&nbsp;</p><p dir="ltr"><strong>Haematotoxicity</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Febrile neutropenia, leukopenia, anaemia, thrombocytopenia and neutropenia occurred very commonly. The frequency of occurrence of hypoprothrombinemia is not known. The risk of neutropenia may be slightly increased when trastuzumab is administered with docetaxel following anthracycline therapy.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pulmonary events</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Severe pulmonary adverse reactions occur in association with the use of Herceptin and have been associated with a fatal outcome. These include, but are not limited to, pulmonary infiltrates, acute respiratory distress syndrome, pneumonia, pneumonitis, pleural effusion, respiratory distress, acute pulmonary oedema and respiratory insufficiency (see section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Description of selected adverse reactions with the subcutaneous formulation</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Administration-related reactions</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the pivotal trial, the rate of all grade ARRs was 37.2&nbsp;% with the Herceptin intravenous formulation and 47.8&nbsp;% with the Herceptin subcutaneous formulation; severe grade 3 reactions were reported in 2.0&nbsp;% and 1.7&nbsp;% of the patients, respectively during the treatment phase; no severe grade 4 or 5 reactions were observed. All of the severe ARRs with the Herceptin subcutaneous formulation occurred during concurrent administration with chemotherapy. The most frequent severe reaction was drug hypersensitivity.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The systemic reactions included hypersensitivity, hypotension, tachycardia, cough, and dyspnoea. The local reactions included erythema, pruritus, oedema, rash and pain at the site of the injection.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Infections</strong></p><p dir="ltr"><strong>The rate of severe infections (NCI CTCAE grade &ge;3) was 5.0&nbsp;% versus 7.1&nbsp;%, in the Herceptin intravenous formulation arm and the Herceptin subcutaneous formulation arm respectively.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The rate of serious infections (most of which were identified because of in-patient hospitalisation or prolongation of existing hospitalisation) was 4.4&nbsp;% in the Herceptin intravenous formulation arm and 8.1&nbsp;% in the Herceptin subcutaneous formulation arm. The difference between formulations was mainly observed during the adjuvant treatment phase (monotherapy) and was mainly due to postoperative wound infections, but also to various other infections such as respiratory tract infections, acute pyelonephritis and sepsis. They resolved within a mean of 13 days in the Herceptin intravenous treatment arm and a mean of 17 days in the Herceptin subcutaneous treatment arm.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hypertensive events</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the pivotal trial BO22227, there were more than twice as many patients reporting all grade hypertension with the Herceptin subcutaneous&nbsp; formulation (4.7&nbsp;% versus 9.8&nbsp;% in the intravenous and subcutaneous formulations respectively), with a greater proportion of patients with severe events (NCI CTCAE grade &ge;3) &lt;1&nbsp;% versus 2.0&nbsp;% the intravenous and subcutaneous formulations respectively. All but one patient who reported severe hypertension had a history of hypertension before they entered the study. Some of the severe events occurred on the day of the injection.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Immunogenicity</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the neoadjuvant-adjuvant EBC study&nbsp; (BO22227), at a median follow-up exceeding 70 months, 10.1% (30/296) of patients treated with Herceptin intravenous and 15.9&nbsp;% (47/295) of patients receiving Herceptin subcutaneous vial developed antibodies against trastuzumab. Neutralizing anti-trastuzumab antibodies were detected in post-baseline samples in 2 of 30 patients in the Herceptin intravenous arm and 3 of 47 in the Herceptin subcutaneous arm. 21.0&nbsp;% of patients treated with Herceptin subcutaneous formulation developed antibodies against the excipient hyaluronidase (rHuPH20).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The clinical relevance of these antibodies is not known.The presence of anti-trastuzumab antibodies had no impact on pharmacokinetics, efficacy (determined by pathological Complete Response [pCR] and event free survival [EFS]) and safety determined by occurrence of administration related reactions (ARRs) of Herceptin intravenous and Herceptin subcutaneous.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Details of risk minimisation measures that are consistent with the EU Risk Management Plan are presented in Section 4.4.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Switching treatment between Herceptin intravenous and Herceptin subcutaneous formulation and vice versa</strong></p><p>&nbsp;</p><ol><li dir="ltr"><p dir="ltr"><strong>Study MO22982 investigated switching between the Herceptin intravenous and Herceptin subcutaneous formulation with a primary objective to evaluate patient preference for either the intravenous or the subcutaneous route of trastuzumab administration. In this trial, 2 cohorts (one using subcutaneous formulation in vial and one using subcutaneous formulation in administration system) were investigated using a 2-arm, cross-over design with 488 patients being randomized to one of two different three-weekly Herceptin treatment sequences (IV [Cycles 1-4]&rarr; SC [Cycles 5-8], or SC [Cycles 1-4]&rarr; IV [Cycles 5-8]). Patients were either na&iuml;ve to Herceptin IV treatment (20.3%) or pre-exposed to Herceptin IV (79.7%). For the sequence IV&rarr;SC (SC vial and SC formulation in administration system cohorts combined), adverse event rates (all grades) were described pre-switching (Cycles 1-4) and post-switching (Cycles 5-8) as 53.8% vs. 56.4%, respectively; for the sequence SC&rarr;IV (SC vial and SC formulation in administration system cohorts combined), adverse event rates (all grades) were described pre- and post-switching as 65.4% vs. 48.7%, respectively.</strong></p></li></ol><p dir="ltr"><strong>Pre-switching rates (Cycles 1-4) for serious adverse events, grade 3 adverse events and treatment discontinuations due to adverse events were low (&lt;5%) and similar to post-switching rates (Cycles 5-8). No grade 4 or grade 5 adverse events were reported.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Reporting of suspected adverse reactions</strong></p><p dir="ltr"><strong>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</strong></p><p>&nbsp;</p><p dir="ltr"><img src="data:image/png;base64,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" alt="" width="598" height="320" vspace="0" hspace="0" border="0" style="width:598px;height:320px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Single doses of up to 960 mg of Herceptin subcutaneous formulation have been administered with no reported untoward effects.</strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies, ATC code: L01XC03</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Herceptin subcutaneous formulation contains recombinant human hyaluronidase (rHuPH20), an enzyme used to increase the dispersion and absorption of co-administered drugs when administered subcutaneously.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Trastuzumab is a recombinant humanised IgG1 monoclonal antibody against the human epidermal growth factor receptor&nbsp;2 (HER2). Overexpression of HER2 is observed in 20%&nbsp; 30% of primary breast cancers. Studies indicate that breast cancer patients whose tumours overexpress HER2 have a shortened diseasefree survival compared to patients whose tumours do not overexpress HER2. The extracellular domain of the receptor (ECD, p105) can be shed into the blood stream and measured in serum samples.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Mechanism of action</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Trastuzumab binds with high affinity and specificity to sub-domain IV, a juxta-membrane region of HER2&rsquo;s extracellular domain. Binding of trastuzumab to HER2 inhibits ligand-independent HER2 signalling and prevents the proteolytic cleavage of its extracellular domain, an activation mechanism of HER2. As a result, trastuzumab has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumour cells that overexpress HER2. Additionally, trastuzumab is a potent mediator of antibodydependent cellmediated cytotoxicity (ADCC). In vitro, trastuzumab-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Detection of HER2 overexpression or HER2 gene amplification</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Detection of HER2 overexpression or HER2 gene amplification in breast cancer</strong></p><p dir="ltr"><strong>Herceptin should only be used in patients whose tumours have HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay. HER2 overexpression should be detected using an immunohistochemistry (IHC)-based assessment of fixed tumour blocks (see section 4.4). HER2 gene amplification should be detected using fluorescence in situ hybridisation (FISH) or chromogenic in situ hybridisation (CISH) of fixed tumour blocks. Patients are eligible for Herceptin treatment if they show strong HER2 overexpression as described by a 3+ score by IHC or a positive FISH or CISH result.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>To ensure accurate and reproducible results, the testing must be performed in a specialised laboratory, which can ensure validation of the testing procedures.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The recommended scoring system to evaluate the IHC staining patterns is as stated in Table 2:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 2: Recommended scoring system to evaluate the IHC staining patterns</strong></p><p>&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>Score&nbsp;</strong></p></td><td><p dir="ltr"><strong>Staining pattern</strong></p></td><td><p dir="ltr"><strong>HER2 overexpression assessment</strong></p></td></tr><tr><td><p dir="ltr"><strong>0</strong></p></td><td><p dir="ltr"><strong>No staining is observed or membrane staining is observed in &lt;&nbsp;10&nbsp;% of the tumour cells&nbsp;</strong></p></td><td><p dir="ltr"><strong>Negative</strong></p></td></tr><tr><td><p dir="ltr"><strong>1+&nbsp;</strong></p></td><td><p dir="ltr"><strong>A faint/barely perceptible membrane staining is detected in &gt;&nbsp;10&nbsp;% of the tumour cells. The cells are only stained in part of their membrane.</strong></p></td><td><p dir="ltr"><strong>Negative</strong></p></td></tr><tr><td><p dir="ltr"><strong>2+</strong></p></td><td><p dir="ltr"><strong>A weak to moderate complete membrane staining is detected in &gt;&nbsp;10&nbsp;% of the tumour cells.</strong></p></td><td><p dir="ltr"><strong>Equivocal</strong></p></td></tr><tr><td><p dir="ltr"><strong>3+&nbsp;</strong></p></td><td><p dir="ltr"><strong>Strong complete membrane staining is detected in &gt;&nbsp;10&nbsp;% of the tumour cells.</strong></p></td><td><p dir="ltr"><strong>Positive</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>In general, FISH is considered positive if the ratio of the HER2 gene copy number per tumour cell to the chromosome 17 copy number is greater than or equal to 2, or if there are more than 4 copies of the HER2 gene per tumour cell if no chromosome 17 control is used.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In general, CISH is considered positive if there are more than 5 copies of the HER2 gene per nucleus in greater than 50&nbsp;% of tumour cells.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For full instructions on assay performance and interpretation please refer to the package inserts of validated FISH and CISH assays. Official recommendations on HER2 testing may also apply.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For any other method that may be used for the assessment of HER2 protein or gene expression, the analyses should only be performed by laboratories that provide adequate state-of-the-art performance of validated methods. Such methods must clearly be precise and accurate enough to demonstrate overexpression of HER2 and must be able to distinguish between moderate (congruent with 2+) and strong (congruent with 3+) overexpression of HER2.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Clinical efficacy and safety</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Metastatic breast cancer</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Intravenous formulation</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Herceptin has been used in clinical trials as monotherapy for patients with MBC who have tumours that overexpress HER2 and who have failed one or more chemotherapy regimens for their metastatic disease (Herceptin alone).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Herceptin has also been used in combination with paclitaxel or docetaxel for the treatment of patients who have not received chemotherapy for their metastatic disease. Patients who had previously received anthracycline-based adjuvant chemotherapy were treated with paclitaxel (175&nbsp;mg/m2 infused over 3 hours) with or without Herceptin. In the pivotal trial of docetaxel (100&nbsp;mg/m2 infused over 1&nbsp;hour) with or without Herceptin, 60&nbsp;% of the patients had received prior anthracycline-based adjuvant chemotherapy. Patients were treated with Herceptin until progression of disease.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The efficacy of Herceptin in combination with paclitaxel in patients who did not receive prior adjuvant anthracyclines has not been studied. However, Herceptin plus docetaxel was efficacious in patients whether or not they had received prior adjuvant anthracyclines.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The test method for HER2 overexpression used to determine eligibility of patients in the pivotal Herceptin monotherapy and Herceptin plus paclitaxel clinical trials employed immunohistochemical staining for HER2 of fixed material from breast tumours using the murine monoclonal antibodies CB11 and 4D5. These tissues were fixed in formalin or Bouin&rsquo;s fixative. This investigative clinical trial assay performed in a central laboratory utilised a 0 to 3+ scale. Patients classified as staining 2+ or 3+ were included, while those staining 0 or 1+ were excluded. Greater than 70&nbsp;% of patients enrolled exhibited 3+ overexpression. The data suggest that beneficial effects were greater among those patients with higher levels of overexpression of HER2 (3+).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The main test method used to determine HER2 positivity in the pivotal trial of docetaxel, with or without Herceptin, was immunohistochemistry. A minority of patients was tested using fluorescence in-situ hybridisation (FISH). In this trial, 87&nbsp;% of patients entered had disease that was IHC3+, and 95&nbsp;% of patients entered had disease that was IHC3+ and/or FISH-positive.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Weekly dosing in metatstatic breast cancer</strong></p><p dir="ltr"><strong>The efficacy results from the monotherapy and combination therapy studies are summarised in Table 3:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 3: Efficacy results from the monotherapy and combination therapy studies</strong></p><p>&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>Parameter</strong></p></td><td><p dir="ltr"><strong>Monotherapy</strong></p></td><td colspan="4"><p dir="ltr"><strong>Combination Therapy</strong></p></td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Herceptin1</strong></p>&nbsp;<p dir="ltr"><strong>N=172</strong></p></td><td><p dir="ltr"><strong>Herceptin plus paclitaxel2</strong></p><p dir="ltr"><strong>N=68</strong></p></td><td><p dir="ltr"><strong>Paclitaxel2</strong></p>&nbsp;<p dir="ltr"><strong>N=77</strong></p></td><td><p dir="ltr"><strong>Herceptin plus docetaxel3</strong></p><p dir="ltr"><strong>N=92</strong></p></td><td><p dir="ltr"><strong>Docetaxel3</strong></p>&nbsp;<p dir="ltr"><strong>N=94</strong></p></td></tr><tr><td><p dir="ltr"><strong>Response rate (95&nbsp;%CI)</strong></p></td><td><p dir="ltr"><strong>18&nbsp;%</strong></p><p dir="ltr"><strong>(13-25)</strong></p></td><td><p dir="ltr"><strong>49&nbsp;%</strong></p><p dir="ltr"><strong>(36- 61)</strong></p></td><td><p dir="ltr"><strong>17&nbsp;%</strong></p><p dir="ltr"><strong>(9-27)</strong></p></td><td><p dir="ltr"><strong>61&nbsp;%</strong></p><p dir="ltr"><strong>(50-71)</strong></p></td><td><p dir="ltr"><strong>34&nbsp;%</strong></p><p dir="ltr"><strong>(25-45)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median duration of response (months) (95&nbsp;%CI)</strong></p></td><td><p dir="ltr"><strong>9.1</strong></p><p dir="ltr"><strong>(5.6-10.3)</strong></p></td><td><p dir="ltr"><strong>8.3</strong></p><p dir="ltr"><strong>(7.3-8.8)</strong></p></td><td><p dir="ltr"><strong>4.6</strong></p><p dir="ltr"><strong>(3.7-7.4)</strong></p></td><td><p dir="ltr"><strong>11.7</strong></p><p dir="ltr"><strong>(9.3&ndash;15.0)</strong></p></td><td><p dir="ltr"><strong>5.7</strong></p><p dir="ltr"><strong>(4.6-7.6)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median TTP (months) (95&nbsp;%CI)</strong></p></td><td><p dir="ltr"><strong>3.2</strong></p><p dir="ltr"><strong>(2.6-3.5)</strong></p></td><td><p dir="ltr"><strong>7.1</strong></p><p dir="ltr"><strong>(6.2-12.0)</strong></p></td><td><p dir="ltr"><strong>3.0</strong></p><p dir="ltr"><strong>(2.0-4.4)</strong></p></td><td><p dir="ltr"><strong>11.7</strong></p><p dir="ltr"><strong>(9.2-13.5)</strong></p></td><td><p dir="ltr"><strong>6.1</strong></p><p dir="ltr"><strong>(5.4-7.2)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median Survival (months) (95&nbsp;%CI)</strong></p></td><td><p dir="ltr"><strong>16.4</strong></p><p dir="ltr"><strong>(12.3-ne)</strong></p></td><td><p dir="ltr"><strong>24.8</strong></p><p dir="ltr"><strong>(18.6-33.7)</strong></p></td><td><p dir="ltr"><strong>17.9</strong></p><p dir="ltr"><strong>(11.2-23.8)</strong></p></td><td><p dir="ltr"><strong>31.2</strong></p><p dir="ltr"><strong>(27.3-40.8)</strong></p></td><td><p dir="ltr"><strong>22.74</strong></p><p dir="ltr"><strong>(19.1-30.8)</strong></p></td></tr></tbody></table><p dir="ltr"><strong>TTP = time to progression; &quot;ne&quot; indicates that it could not be estimated or it was not yet reached.</strong></p><p dir="ltr"><strong>1. Study H0649g: IHC3+ patient subset</strong></p><p dir="ltr"><strong>2. Study H0648g: IHC3+ patient subset</strong></p><p dir="ltr"><strong>3. Study M77001: Full analysis set (intent-to-treat), 24 months results</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Combination treatment with Herceptin and anastrozole</strong></p><p dir="ltr"><strong>Herceptin has been studied in combination with anastrozole for first line treatment of MBC in HER2 overexpressing, hormone-receptor (i.e. estrogen-receptor (ER) and/or progesterone-receptor (PR)) positive postmenopausal patients. Progression free survival was doubled in the Herceptin plus anastrozole arm compared to anastrozole (4.8 months versus 2.4 months). For the other parameters the improvements seen for the combination were for overall response (16.5&nbsp;% versus 6.7&nbsp;%); clinical benefit rate (42.7&nbsp;% versus 27.9&nbsp;%); time to progression (4.8 months versus 2.4 months). For time to response and duration of response no difference could be recorded between the arms. The median overall survival was extended by 4.6 months for patients in the combination arm. The difference was not statistically significant, however more than half of the patients in the anastrozole alone arm crossed over to a Herceptin containing regimen after progression of disease.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Three -weekly dosing in metastatic breast cancer</strong></p><p dir="ltr"><strong>The efficacy results from the non-comparative monotherapy and combination therapy studies are summarised in Table 4:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 4: Efficacy results from the non-comparative monotherapy and combination therapy studies</strong></p><p>&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>Parameter</strong></p></td><td colspan="2"><p dir="ltr"><strong>Monotherapy</strong></p></td><td colspan="2"><p dir="ltr"><strong>Combination Therapy</strong></p></td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Herceptin1</strong></p>&nbsp;<p dir="ltr"><strong>N=105</strong></p></td><td><p dir="ltr"><strong>Herceptin2</strong></p>&nbsp;<p dir="ltr"><strong>N=72</strong></p></td><td><p dir="ltr"><strong>Herceptin plus paclitaxel3</strong></p><p dir="ltr"><strong>N=32</strong></p></td><td><p dir="ltr"><strong>Herceptin plus&nbsp;</strong></p><p dir="ltr"><strong>docetaxel4</strong></p><p dir="ltr"><strong>N=110</strong></p></td></tr><tr><td><p dir="ltr"><strong>Response rate (95&nbsp;%CI)</strong></p></td><td><p dir="ltr"><strong>24&nbsp;%</strong></p><p dir="ltr"><strong>(15-35)</strong></p></td><td><p dir="ltr"><strong>27&nbsp;%</strong></p><p dir="ltr"><strong>(14-43)</strong></p></td><td><p dir="ltr"><strong>59&nbsp;%</strong></p><p dir="ltr"><strong>(41-76)</strong></p></td><td><p dir="ltr"><strong>73&nbsp;%</strong></p><p dir="ltr"><strong>(63-81)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median duration of response (months) (range)</strong></p></td><td><p dir="ltr"><strong>10.1</strong></p><p dir="ltr"><strong>(2.8-35.6)</strong></p></td><td><p dir="ltr"><strong>7.9</strong></p><p dir="ltr"><strong>(2.1-18.8)</strong></p></td><td><p dir="ltr"><strong>10.5</strong></p><p dir="ltr"><strong>(1.8-21)</strong></p></td><td><p dir="ltr"><strong>13.4</strong></p><p dir="ltr"><strong>(2.1-55.1)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median TTP (months) (95&nbsp;%CI)</strong></p></td><td><p dir="ltr"><strong>3.4</strong></p><p dir="ltr"><strong>(2.8-4.1)</strong></p></td><td><p dir="ltr"><strong>7.7</strong></p><p dir="ltr"><strong>(4.2-8.3)</strong></p></td><td><p dir="ltr"><strong>12.2</strong></p><p dir="ltr"><strong>(6.2-ne)</strong></p></td><td><p dir="ltr"><strong>13.6</strong></p><p dir="ltr"><strong>(11-16)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Median Survival (months) (95&nbsp;%CI)</strong></p></td><td><p dir="ltr"><strong>ne</strong></p></td><td><p dir="ltr"><strong>ne</strong></p></td><td><p dir="ltr"><strong>ne</strong></p></td><td><p dir="ltr"><strong>47.3</strong></p><p dir="ltr"><strong>(32-ne)</strong></p></td></tr></tbody></table><p dir="ltr"><strong>TTP = time to progression; &quot;ne&quot; indicates that it could not be estimated or it was not yet reached.</strong></p><p dir="ltr"><strong>1. Study WO16229: loading dose 8&nbsp;mg/kg, followed by 6&nbsp;mg/kg 3 weekly schedule</strong></p><p dir="ltr"><strong>2. Study MO16982: loading dose 6&nbsp;mg/kg weekly x 3; followed by 6&nbsp;mg/kg 3-weekly schedule</strong></p><p dir="ltr"><strong>3. Study BO15935</strong></p><p dir="ltr"><strong>4. Study MO16419</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Sites of progression</strong></p><p dir="ltr"><strong>The frequency of progression in the liver was significantly reduced in patients treated with the combination of Herceptin and paclitaxel, compared to paclitaxel alone (21.8&nbsp;% versus 45.7&nbsp;%; p=0.004). More patients treated with Herceptin and paclitaxel progressed in the central nervous system than those treated with paclitaxel alone (12.6&nbsp;% versus 6.5&nbsp;%; p=0.377).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Early breast cancer (adjuvant setting)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Intravenous formulation</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Early breast cancer is defined as non-metastatic primary invasive carcinoma of the breast.</strong></p><p dir="ltr"><strong>In the adjuvant treatment setting, Herceptin was investigated in 4 large multicentre, randomised, trials.</strong></p><p dir="ltr"><strong>- Study BO16348 was designed to compare one and two years of three-weekly Herceptin treatment versus observation in patients with HER2 positive EBC following surgery, established chemotherapy and radiotherapy (if applicable). In addition, comparison of two years of Herceptin treatment versus one year of Herceptin treatment was performed. Patients assigned to receive Herceptin were given an initial loading dose of 8&nbsp;mg/kg, followed by 6&nbsp;mg/kg every three weeks for either one or two years.</strong></p><p dir="ltr"><strong>- Studies NSABP B-31 and NCCTG N9831 that comprise the joint analysis were designed to investigate the clinical utility of combining Herceptin treatment with paclitaxel following AC chemotherapy, additionally the NCCTG N9831 study also investigated adding Herceptin sequentially to AC&rarr;P chemotherapy in patients with HER2 positive EBC following surgery.</strong></p><p dir="ltr"><strong>- Study BCIRG 006 study was designed to investigate combining Herceptin treatment with docetaxel either following AC chemotherapy or in combination with docetaxel and carboplatin in patients with HER2 positive EBC following surgery.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Early breast cancer in the BO16348 Study was limited to operable, primary, invasive adenocarcinoma of the breast, with axillary nodes positive or axillary nodes negative if tumors at least 1 cm in diameter.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the joint analysis of the NSABP B-31 and NCCTG N9831 studies, EBC was limited to women with operable breast cancer at high risk, defined as HER2-positive and axillary lymph node positive or HER2 positive and lymph node negative with high risk features (tumor size &gt; 1 cm and ER negative or tumor size &gt; 2 cm, regardless of hormonal status).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the BCIRG 006 study HER2 positive, EBC was defined as either lymph node positive or high risk node negative patients with no (pN0) lymph node involvement, and at least 1 of the following factors: tumour size greater than 2 cm, estrogen receptor and progesterone receptor negative, histological and/or nuclear grade 2-3, or age &lt; 35 years.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The efficacy results from study BO16348 following 12 months* and 8 years** median follow-up are summarized in the Table 5:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 5: Efficacy results from study BO16348</strong></p><p>&nbsp;</p><table><tbody><tr><td>&nbsp;</td><td colspan="2"><p dir="ltr"><strong>Median follow-up<br />12&nbsp;months*</strong></p></td><td colspan="2"><p dir="ltr"><strong>Median follow-up<br />8&nbsp;years**</strong></p></td></tr><tr><td><p dir="ltr"><strong>Parameter</strong></p></td><td><p dir="ltr"><strong>Observation</strong></p><p dir="ltr"><strong>N=1693</strong></p></td><td><p dir="ltr"><strong>Herceptin<br />1&nbsp;Year</strong></p><p dir="ltr"><strong>N = 1693</strong></p></td><td><p dir="ltr"><strong>Observation<br />N= 1697***</strong></p></td><td><p dir="ltr"><strong>Herceptin<br />1&nbsp;Year</strong></p><p dir="ltr"><strong>N = 1702***</strong></p></td></tr><tr><td><p dir="ltr"><strong>Disease-free survival</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>- No. patients with event</strong></p></td><td><p dir="ltr"><strong>219 (12.9 %)</strong></p></td><td><p dir="ltr"><strong>127 (7.5 %)</strong></p></td><td><p dir="ltr"><strong>570 (33.6 %)</strong></p></td><td><p dir="ltr"><strong>471 (27.7 %)</strong></p></td></tr><tr><td><p dir="ltr"><strong>- No. patients without event</strong></p></td><td><p dir="ltr"><strong>1474 (87.1 %)</strong></p></td><td><p dir="ltr"><strong>1566 (92.5 %)</strong></p></td><td><p dir="ltr"><strong>1127 (66.4 %)</strong></p></td><td><p dir="ltr"><strong>1231 (72.3 %)</strong></p></td></tr><tr><td><p dir="ltr"><strong>P-value versus Observation</strong></p></td><td colspan="2"><p dir="ltr"><strong>&lt;&nbsp;0.0001</strong></p></td><td colspan="2"><p dir="ltr"><strong>&lt;&nbsp;0.0001</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hazard Ratio versus Observation</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.54</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.76</strong></p></td></tr><tr><td><p dir="ltr"><strong>Recurrence-free survival</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>- No. patients with event</strong></p></td><td><p dir="ltr"><strong>208 (12.3 %)</strong></p></td><td><p dir="ltr"><strong>113 (6.7 %)</strong></p></td><td><p dir="ltr"><strong>506 (29.8 %)</strong></p></td><td><p dir="ltr"><strong>399 (23.4 %)</strong></p></td></tr><tr><td><p dir="ltr"><strong>- No. patients without event</strong></p></td><td><p dir="ltr"><strong>1485 (87.7 %)</strong></p></td><td><p dir="ltr"><strong>1580 (93.3 %)</strong></p></td><td><p dir="ltr"><strong>1191 (70.2 %)</strong></p></td><td><p dir="ltr"><strong>1303 (76.6 %)</strong></p></td></tr><tr><td><p dir="ltr"><strong>P-value versus Observation</strong></p></td><td colspan="2"><p dir="ltr"><strong>&lt;&nbsp;0.0001</strong></p></td><td colspan="2"><p dir="ltr"><strong>&lt;&nbsp;0.0001</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hazard Ratio versus Observation</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.51</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.73</strong></p></td></tr><tr><td><p dir="ltr"><strong>Distant disease-free survival</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>- No. patients with event</strong></p></td><td><p dir="ltr"><strong>184 (10.9 %)</strong></p></td><td><p dir="ltr"><strong>99 (5.8 %)</strong></p></td><td><p dir="ltr"><strong>488 (28.8 %)</strong></p></td><td><p dir="ltr"><strong>399 (23.4 %)</strong></p></td></tr><tr><td><p dir="ltr"><strong>- No. patients without event</strong></p></td><td><p dir="ltr"><strong>1508 (89.1 %)</strong></p></td><td><p dir="ltr"><strong>1594 (94.6 %)</strong></p></td><td><p dir="ltr"><strong>1209 (71.2 %)</strong></p></td><td><p dir="ltr"><strong>1303 (76.6 %)</strong></p></td></tr><tr><td><p dir="ltr"><strong>P-value versus Observation</strong></p></td><td colspan="2"><p dir="ltr"><strong>&lt;&nbsp;0.0001</strong></p></td><td colspan="2"><p dir="ltr"><strong>&lt;&nbsp;0.0001</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hazard Ratio versus Observation</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.50</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.76</strong></p></td></tr><tr><td><p dir="ltr"><strong>Overall survival (death)</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>- No. patients with event</strong></p></td><td><p dir="ltr"><strong>40 (2.4 %)</strong></p></td><td><p dir="ltr"><strong>31 (1.8 %)</strong></p></td><td><p dir="ltr"><strong>350 (20.6 %)</strong></p></td><td><p dir="ltr"><strong>278 (16.3 %)</strong></p></td></tr><tr><td><p dir="ltr"><strong>- No. patients without event</strong></p></td><td><p dir="ltr"><strong>1653 (97.6 %)</strong></p></td><td><p dir="ltr"><strong>1662 (98.2 %)</strong></p></td><td><p dir="ltr"><strong>1347 (79.4 %)</strong></p></td><td><p dir="ltr"><strong>1424 (83.7 %)</strong></p></td></tr><tr><td><p dir="ltr"><strong>P-value versus Observation</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.24</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.0005</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hazard Ratio versus Observation</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.75</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.76</strong></p></td></tr></tbody></table><p dir="ltr"><strong>*Co-primary endpoint of DFS of 1 year versus observation met the pre-defined statistical boundary</strong></p><p dir="ltr"><strong>**Final analysis (including crossover of 52 % of patients from the observation arm to Herceptin)</strong></p><p dir="ltr"><strong>*** There is a discrepancy in the overall sample size due to a small number of patients who were randomized after the cut-off date for the 12-month median follow-up analysis</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The efficacy results from the interim efficacy analysis crossed the protocol pre-specified statistical boundary for the comparison of 1-year of Herceptin versus observation. After a median follow-up of 12 months, the hazard ratio (HR) for disease free survival (DFS) was 0.54 (95 % CI 0.44, 0.67) which translates into an absolute benefit, in terms of a 2-year disease-free survival rate, of 7.6 percentage points (85.8&nbsp;% versus 78.2&nbsp;%) in favour of the Herceptin arm.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>A final analysis was performed after a median follow-up of 8 years, which showed that 1 year Herceptin treatment is associated with a 24 % risk reduction compared to observation only (HR=0.76, 95 % CI 0.67, 0.86). This translates into an absolute benefit in terms of an 8 year disease free survival rate of 6.4 percentage points in favour of 1 year Herceptin treatment.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In this final analysis, extending Herceptin treatment for a duration of two years did not show additional benefit over treatment for 1 year [DFS HR in the intent to treat (ITT) population of 2 years versus 1 year=0.99 (95 % CI: 0.87, 1.13), p-value=0.90 and OS HR=0.98 (0.83, 1.15); p-value= 0.78]. The rate of asymptomatic cardiac dysfunction was increased in the 2-year treatment arm (8.1 % versus 4.6 % in the 1-year treatment arm). More patients experienced at least one grade 3 or 4 adverse event in the 2-year treatment arm (20.4 %) compared with the 1-year treatment arm (16.3 %).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the NSABP B-31 and NCCTG N9831 studies Herceptin was administered in combination with paclitaxel, following AC chemotherapy.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Doxorubicin and cyclophosphamide were administered concurrently as follows:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>- intravenous push doxorubicin, at 60&nbsp;mg/ m2, given every 3 weeks for 4 cycles.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>- intravenous cyclophosphamide, at 600&nbsp;mg/ m2 over 30 minutes, given every 3 weeks for 4 cycles.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paclitaxel, in combination with Herceptin, was administered as follows:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>- intravenous paclitaxel - 80&nbsp;mg/m2 as a continuous intravenous infusion, given every week for 12 weeks.</strong></p><p dir="ltr"><strong>or</strong></p><p dir="ltr"><strong>- intravenous paclitaxel - 175&nbsp;mg/m2 as a continuous intravenous infusion, given every 3 weeks for 4 cycles (day 1 of each cycle).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The efficacy results from the joint analysis of the NSABP B-31 and NCCTG 9831 trials at the time of the definitive analysis of DFS* are summarized in Table 6. The median duration of follow up was 1.8 years for the patients in the AC&rarr;P arm and 2.0 years for patients in the AC&rarr;PH arm.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 6: Summary of Efficacy results from the joint analysis studies NSABP B-31 and NCCTG N9831 at the time of the definitive DFS analysis*</strong></p><table><tbody><tr><td><p dir="ltr"><strong>Parameter</strong></p></td><td><p dir="ltr"><strong>AC&rarr;P</strong></p><p dir="ltr"><strong>(n=1679)</strong></p></td><td><p dir="ltr"><strong>AC&rarr;PH</strong></p><p dir="ltr"><strong>(n=1672)</strong></p></td><td colspan="2"><p dir="ltr"><strong>Hazard Ratio vs AC&rarr;P</strong></p><p dir="ltr"><strong>(95&nbsp;% CI)</strong></p><p dir="ltr"><strong>p-value</strong></p></td></tr><tr><td><p dir="ltr"><strong>Disease-free survival</strong></p><p dir="ltr"><strong>No. patients with event (%)</strong></p></td><td>&nbsp;<p dir="ltr"><strong>261 (15.5)</strong></p></td><td>&nbsp;<p dir="ltr"><strong>133 (8.0)</strong></p></td><td colspan="2">&nbsp;<p dir="ltr"><strong>0.48 (0.39, 0.59)</strong></p><p dir="ltr"><strong>p&lt;0.0001</strong></p></td></tr><tr><td><p dir="ltr"><strong>Distant Recurrence</strong></p><p dir="ltr"><strong>No. patients with event</strong></p></td><td>&nbsp;<p dir="ltr"><strong>193 (11.5)</strong></p></td><td>&nbsp;<p dir="ltr"><strong>96 (5.7)</strong></p></td><td colspan="2">&nbsp;<p dir="ltr"><strong>0.47 (0.37, 0.60)</strong></p><p dir="ltr"><strong>p&lt;0.0001</strong></p></td></tr><tr><td><p dir="ltr"><strong>Death (OS event):</strong></p><p dir="ltr"><strong>No. patients with event&nbsp;</strong></p></td><td>&nbsp;<p dir="ltr"><strong>92 (5.5)</strong></p></td><td>&nbsp;<p dir="ltr"><strong>62 (3.7)</strong></p></td><td colspan="2">&nbsp;<p dir="ltr"><strong>0.67 (0.48, 0.92)</strong></p><p dir="ltr"><strong>p=0.014**</strong></p></td></tr></tbody></table><p dir="ltr"><strong>A: doxorubicin; C: cyclophosphamide; P: paclitaxel; H: trastuzumab</strong></p><p dir="ltr"><strong>* at median duration of follow up of 1.8 years for the patients in the AC&rarr;P arm and 2.0 years for patients in the AC&rarr;PH arm</strong></p><p dir="ltr"><strong>** p value for OS did not cross the pre-specified statistical boundary for comparison of AC&rarr;PH vs. AC&rarr;P</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For the primary endpoint, DFS, the addition of Herceptin to paclitaxel chemotherapy resulted in a 52&nbsp;% decrease in the risk of disease recurrence. The hazard ratio translates into an absolute benefit, in terms of 3-year disease-free survival rate estimates of 11.8 percentage points (87.2&nbsp;% versus 75.4&nbsp;%) in favour of the AC&rarr;PH (Herceptin) arm.</strong></p><p dir="ltr"><strong>At the time of a safety update after a median of 3.5-3.8 years follow up, an analysis of DFS reconfirms the magnitude of the benefit shown in the definitive analysis of DFS. Despite the cross-over to Herceptin in the control arm, the addition of Herceptin to paclitaxel chemotherapy resulted in a 52&nbsp;% decrease in the risk of disease recurrence. The addition of Herceptin to paclitaxel chemotherapy also resulted in a 37&nbsp;% decrease in the risk of death.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The pre-planned final analysis of OS from the joint analysis of studies NSABP B-31 and NCCTG N9831 was performed when 707 deaths had occurred (median follow-up 8.3 years in the AC&rarr;PH group). Treatment with AC&rarr;PH resulted in a&nbsp;statistically significant improvement in OS compared with AC&rarr;P (stratified HR=0.64; 95% CI [0.55, 0.74]; log-rank p-value&nbsp;&lt;&nbsp;0.0001).&nbsp; At 8 years, the survival rate was estimated to be 86.9% in the AC&rarr;PH arm and 79.4% in the AC&rarr;P arm, an&nbsp;absolute benefit of 7.4% (95% CI 4.9%, 10.0%).</strong></p><p dir="ltr"><strong>The final OS results from the joint analysis of studies NSABP B-31 and NCCTG N9831 are summarized in Table 7:</strong></p><p dir="ltr"><strong>Table&nbsp;7: Final Overall Survival Analysis from the joint analysis of trials NSABP<br />B-31 and NCCTG N9831&nbsp;</strong></p><p>&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>Parameter</strong></p></td><td><p dir="ltr"><strong>AC&rarr;P</strong></p><p dir="ltr"><strong>(N=2032)</strong></p></td><td><p dir="ltr"><strong>AC&rarr;PH</strong></p><p dir="ltr"><strong>(N=2031)</strong></p></td><td><p dir="ltr"><strong>p-value versus AC&rarr;P</strong></p></td><td><p dir="ltr"><strong>Hazard Ratio versus AC&rarr;P</strong></p><p dir="ltr"><strong>(95% CI)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Death (OS event):</strong></p><p dir="ltr"><strong>No. patients with event (%)</strong></p></td><td>&nbsp;<p dir="ltr"><strong>418 (20.6%)</strong></p></td><td>&nbsp;<p dir="ltr"><strong>289 (14.2%)</strong></p></td><td>&nbsp;<p dir="ltr"><strong>&lt; 0.0001</strong></p></td><td>&nbsp;<p dir="ltr"><strong>0.64</strong></p><p dir="ltr"><strong>(0.55, 0.74)</strong></p></td></tr></tbody></table><p dir="ltr"><strong>A: doxorubicin; C: cyclophosphamide; P: paclitaxel; H: trastuzumab</strong></p><p dir="ltr"><strong>DFS analysis was also performed at the final analysis of OS from the joint analysis of studies NSABP&nbsp;B-31 and NCCTG N9831. The updated DFS analysis results (stratified HR = 0.61; 95% CI [0.54, 0.69])&nbsp;showed&nbsp;a similar DFS benefit&nbsp;compared to&nbsp;the definitive primary DFS analysis, despite 24.8% patients in the AC&rarr;P arm who crossed over to receive Herceptin. At 8 years, the disease-free survival rate was estimated to be 77.2% (95% CI: 75.4, 79.1) in the AC&rarr;PH arm, an absolute benefit of 11.8% compared with the AC&rarr;P arm.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the BCIRG 006 study Herceptin was administered either in combination with docetaxel, following AC chemotherapy (AC&rarr;DH) or in combination with docetaxel and carboplatin (DCarbH).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Docetaxel was administered as follows:</strong></p><p dir="ltr"><strong>- intravenous docetaxel - 100&nbsp;mg/m2 as an intravenous infusion over 1 hour, given every 3 weeks for 4 cycles (day 2 of first docetaxel cycle, then day 1 of each subsequent cycle)</strong></p><p dir="ltr"><strong>or&nbsp;</strong></p><p dir="ltr"><strong>- intravenous docetaxel - 75&nbsp;mg/m2 as an intravenous infusion over 1 hour, given every 3 weeks for 6 cycles (day 2 of cycle 1, then day 1 of each subsequent cycle)</strong></p><p dir="ltr"><strong>which was followed by:</strong></p><p dir="ltr"><strong>- carboplatin &ndash; at target AUC = 6&nbsp;mg/mL/min administered by intravenous infusion over 30-60 minutes repeated every 3 weeks for a total of six cycles</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Herceptin was administered weekly with chemotherapy and 3 weekly thereafter for a total of 52 weeks.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The efficacy results from the BCIRG&nbsp;006 are summarized in Tables 8 and 9. The median duration of follow up was 2.9 years in the AC&rarr;D arm and 3.0 years in each of the AC&rarr;DH and DCarbH arms.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 8: Overview of efficacy analyses BCIRG&nbsp;006 AC&rarr;D versus AC&rarr;DH</strong></p><p>&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>Parameter</strong></p></td><td><p dir="ltr"><strong>AC&rarr;D</strong></p><p dir="ltr"><strong>(n=1073)</strong></p></td><td><p dir="ltr"><strong>AC&rarr;DH</strong></p><p dir="ltr"><strong>(n=1074)</strong></p></td><td colspan="2"><p dir="ltr"><strong>Hazard Ratio vs AC&rarr;D</strong></p><p dir="ltr"><strong>(95&nbsp;% CI)</strong></p><p dir="ltr"><strong>p-value</strong></p></td></tr><tr><td><p dir="ltr"><strong>Disease-free survival</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td colspan="2">&nbsp;</td></tr><tr><td><p dir="ltr"><strong>No. patients with event</strong></p></td><td><p dir="ltr"><strong>195</strong></p></td><td><p dir="ltr"><strong>134</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.61 (0.49, 0.77)</strong></p><p dir="ltr"><strong>p&lt;0.0001</strong></p></td></tr><tr><td><p dir="ltr"><strong>Distant recurrence</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td colspan="2">&nbsp;</td></tr><tr><td><p dir="ltr"><strong>No. patients with event</strong></p></td><td><p dir="ltr"><strong>144</strong></p></td><td><p dir="ltr"><strong>95</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.59 (0.46, 0.77)</strong></p><p dir="ltr"><strong>p&lt;0.0001</strong></p></td></tr><tr><td><p dir="ltr"><strong>Death (OS event)</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td colspan="2">&nbsp;</td></tr><tr><td><p dir="ltr"><strong>No. patients with event</strong></p></td><td><p dir="ltr"><strong>80</strong></p></td><td><p dir="ltr"><strong>49</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.58 (0.40, 0.83)</strong></p><p dir="ltr"><strong>p=0.0024</strong></p></td></tr></tbody></table><p dir="ltr"><strong>AC&rarr;D = doxorubicin plus cyclophosphamide, followed by docetaxel; AC&rarr;DH = doxorubicin plus cyclophosphamide, followed by docetaxel plus trastuzumab; CI = confidence interval</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 9: Overview of efficacy analyses BCIRG&nbsp;006 AC&rarr;D versus DCarbH</strong></p><p>&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>Parameter</strong></p></td><td><p dir="ltr"><strong>AC&rarr;D</strong></p><p dir="ltr"><strong>(n=1073)</strong></p></td><td><p dir="ltr"><strong>DCarbH</strong></p><p dir="ltr"><strong>(n=1074)</strong></p></td><td colspan="2"><p dir="ltr"><strong>Hazard Ratio vs AC&rarr;D</strong></p><p dir="ltr"><strong>(95&nbsp;% CI)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Disease-free survival</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td colspan="2">&nbsp;</td></tr><tr><td><p dir="ltr"><strong>No. patients with event</strong></p></td><td><p dir="ltr"><strong>195</strong></p></td><td><p dir="ltr"><strong>145</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.67 (0.54, 0.83)</strong></p><p dir="ltr"><strong>p=0.0003</strong></p></td></tr><tr><td><p dir="ltr"><strong>Distant recurrence</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td colspan="2">&nbsp;</td></tr><tr><td><p dir="ltr"><strong>No. patients with event</strong></p></td><td><p dir="ltr"><strong>144</strong></p></td><td><p dir="ltr"><strong>103</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.65 (0.50, 0.84)</strong></p><p dir="ltr"><strong>p=0.0008</strong></p></td></tr><tr><td><p dir="ltr"><strong>Death (OS event)</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td colspan="2">&nbsp;</td></tr><tr><td><p dir="ltr"><strong>No. patients with event</strong></p></td><td><p dir="ltr"><strong>80</strong></p></td><td><p dir="ltr"><strong>56</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.66 (0.47, 0.93)</strong></p><p dir="ltr"><strong>p=0.0182</strong></p></td></tr></tbody></table><p dir="ltr"><strong>AC&rarr;D = doxorubicin plus cyclophosphamide, followed by docetaxel; DCarbH = docetaxel, carboplatin and trastuzumab; CI = confidence interval</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the BCIRG 006 study for the primary endpoint, DFS, the hazard ratio translates into an absolute benefit, in terms of 3-year disease-free survival rate estimates of 5.8 percentage points (86.7&nbsp;% versus 80.9&nbsp;%) in favour of the AC&rarr;DH (Herceptin) arm and 4.6 percentage points (85.5&nbsp;% versus 80.9&nbsp;%) in favour of the DCarbH (Herceptin) arm compared to AC&rarr;D.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In study BCIRG 006, 213/1075 patients in the DCarbH (TCH) arm, 221/1074&nbsp;patients in the AC&rarr;DH (AC&rarr;TH) arm, and 217/1073 in the AC&rarr;D (AC&rarr;T) arm had a Karnofsky performance status &le;90 (either 80 or 90). No disease-free survival (DFS) benefit was noticed in this subgroup of patients (hazard ratio&nbsp;=&nbsp;1.16, 95&nbsp;% CI [0.73, 1.83] for DCarbH (TCH) versus AC&rarr;D (AC&rarr;T); hazard ratio 0.97, 95&nbsp;% CI [0.60, 1.55] for AC&rarr;DH (AC&rarr;TH) versus AC&rarr;D).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In addition a post-hoc exploratory analysis was performed on the data sets from the joint analysis (JA) NSABP B-31/NCCTG N9831* and BCIRG006 clinical studies combining DFS events and symptomatic cardiac events and summarised in Table 10:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 10: Post-hoc exploratory analysis results from the joint analysis NSABP B-31/NCCTG N9831* and BCIRG006 clinical studies combining DFS events and symptomatic cardiac events</strong></p><p>&nbsp;</p><table><tbody><tr><td>&nbsp;</td><td><p dir="ltr"><strong>AC&rarr;PH</strong></p><p dir="ltr"><strong>(vs. AC&rarr;P)</strong></p><p dir="ltr"><strong>(NSABP B-31 and NCCTG N9831)*</strong></p></td><td><p dir="ltr"><strong>AC&rarr;DH</strong></p><p dir="ltr"><strong>(vs. AC&rarr;D)</strong></p><p dir="ltr"><strong>(BCIRG 006)</strong></p></td><td><p dir="ltr"><strong>DCarbH</strong></p><p dir="ltr"><strong>(vs. AC&rarr;D)</strong></p><p dir="ltr"><strong>(BCIRG 006)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Primary efficacy analysis</strong></p><p dir="ltr"><strong>DFS Hazard ratios</strong></p><p dir="ltr"><strong>(95&nbsp;% CI)</strong></p><p dir="ltr"><strong>p-value</strong></p></td><td>&nbsp;<p dir="ltr"><strong>0.48</strong></p><p dir="ltr"><strong>(0.39, 0.59)</strong></p><p dir="ltr"><strong>p&lt;0.0001</strong></p></td><td>&nbsp;<p dir="ltr"><strong>0.61</strong></p><p dir="ltr"><strong>(0.49, 0.77)</strong></p><p dir="ltr"><strong>p&lt; 0.0001</strong></p></td><td>&nbsp;<p dir="ltr"><strong>0.67</strong></p><p dir="ltr"><strong>(0.54, 0.83)</strong></p><p dir="ltr"><strong>p=0.0003</strong></p></td></tr><tr><td><p dir="ltr"><strong>Long term follow-up efficacy analysis**</strong></p><p dir="ltr"><strong>DFS Hazard ratios</strong></p><p dir="ltr"><strong>(95 % CI)</strong></p><p dir="ltr"><strong>p-value</strong></p></td><td>&nbsp;<p dir="ltr"><strong>0.61</strong></p><p dir="ltr"><strong>(0.54, 0.69)</strong></p><p dir="ltr"><strong>p&lt;0.0001</strong></p></td><td>&nbsp;<p dir="ltr"><strong>0.72</strong></p><p dir="ltr"><strong>(0.61, 0.85)</strong></p><p dir="ltr"><strong>p&lt;0.0001</strong></p></td><td>&nbsp;<p dir="ltr"><strong>0.77</strong></p><p dir="ltr"><strong>(0.65, 0.90)</strong></p><p dir="ltr"><strong>p=0.0011</strong></p></td></tr><tr><td><p dir="ltr"><strong>Post-hoc exploratory analysis with DFS and symptomatic cardiac events</strong></p><p dir="ltr"><strong>Long term follow-up**</strong></p><p dir="ltr"><strong>Hazard ratios</strong></p><p dir="ltr"><strong>(95&nbsp;% CI)</strong></p></td><td><br /><br />&nbsp;<p dir="ltr"><strong>0.67</strong></p><p dir="ltr"><strong>(0.60, 0.75)</strong></p></td><td><br /><br />&nbsp;<p dir="ltr"><strong>0.77</strong></p><p dir="ltr"><strong>(0.66, 0.90)</strong></p></td><td><br /><br />&nbsp;<p dir="ltr"><strong>0.77</strong></p><p dir="ltr"><strong>(0.66, 0.90)</strong></p></td></tr></tbody></table><p dir="ltr"><strong>A: doxorubicin; C: cyclophosphamide; P: paclitaxel; D: docetaxel; Carb: carboplatin; H: trastuzumab</strong></p><p dir="ltr"><strong>CI = confidence interval</strong></p><p dir="ltr"><strong>* At the time of the definitive analysis of DFS. Median duration of follow up was 1.8 years in the AC&rarr;P arm and 2.0 years in the AC&rarr;PH arm</strong></p><p dir="ltr"><strong>** Median duration of long term follow-up for the Joint Analysis clinical studies was 8.3 years (range: 0.1 to 12.1) for the AC&rarr;PH arm and 7.9 years (range: 0.0 to 12.2) for the AC&rarr;P arm;&nbsp; Median duration of long term followup for the BCIRG 006 study was 10.3&nbsp;years in both the AC&rarr;D arm (range: 0.0 to 12.6) and the DCarbH arm (range: 0.0 to 13.1), and was 10.4&nbsp;years (range: 0.0 to 12.7) in the AC&rarr;DH arm</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Early breast cancer &ndash; (neoadjuvant-adjuvant setting)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Intravenous formulation</strong></p><p>&nbsp;</p><p dir="ltr"><strong>So far, no results are available which compare the efficacy of Herceptin administered with chemotherapy in the adjuvant setting with that obtained in the neo-adjuvant/adjuvant setting.<br /><br />In the neoadjuvant-adjuvant treatment setting, study MO16432, a multicentre randomised trial, was designed to investigate the clinical efficacy of concurrent administration of Herceptin with neoadjuvant chemotherapy including both an anthracycline and a taxane, followed by adjuvant Herceptin, up to a total treatment duration of 1 year. The study recruited patients with newly diagnosed locally advanced (Stage III) or inflammatory EBC. Patients with HER2+ tumours were randomised to receive either neoadjuvant chemotherapy concurrently with neoadjuvant-adjuvant Herceptin, or neoadjuvant chemotherapy alone.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In study MO16432, Herceptin (8 mg/kg loading dose, followed by 6 mg/kg maintenance every 3 weeks) was administered concurrently with 10 cycles of neoadjuvant chemotherapy</strong></p><p>&nbsp;</p><p dir="ltr"><strong>as follows:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>- Doxorubicin 60mg/m2 and paclitaxel 150 mg/m2, administered 3-weekly for 3 cycles,</strong></p><p>&nbsp;</p><p dir="ltr"><strong>which was followed by</strong></p><p dir="ltr"><strong>- Paclitaxel 175 mg/m2 administered 3-weekly for 4 cycles,</strong></p><p>&nbsp;</p><p dir="ltr"><strong>which was followed by</strong></p><p dir="ltr"><strong>- CMF on day 1 and 8 every 4 weeks for 3 cycles</strong></p><p>&nbsp;</p><p dir="ltr"><strong>which was followed after surgery by</strong></p><p dir="ltr"><strong>- additional cycles of adjuvant Herceptin (to complete 1 year of treatment)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The efficacy results from Study MO16432 are summarized in Table 11. The median duration of follow-up in the Herceptin arm was 3.8 years.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 11: Efficacy results from MO16432</strong></p><p>&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>Parameter</strong></p></td><td><p dir="ltr"><strong>Chemo + Herceptin</strong></p><p dir="ltr"><strong>(n=115)</strong></p></td><td><p dir="ltr"><strong>Chemo only</strong></p><p dir="ltr"><strong>(n=116)</strong></p></td><td colspan="2">&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Event-free survival</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td colspan="2"><p dir="ltr"><strong>Hazard Ratio</strong></p><p dir="ltr"><strong>(95&nbsp;% CI)</strong></p></td></tr><tr><td><p dir="ltr"><strong>No. patients with event</strong></p></td><td><p dir="ltr"><strong>46</strong></p></td><td><p dir="ltr"><strong>59</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.65 (0.44, 0.96)<br />p=0.0275</strong></p></td></tr><tr><td><p dir="ltr"><strong>Total pathological complete<br />response* (95&nbsp;% CI)</strong></p></td><td><p dir="ltr"><strong>40&nbsp;%</strong></p><p dir="ltr"><strong>(31.0, 49.6)</strong></p></td><td><p dir="ltr"><strong>20.7&nbsp;%</strong></p><p dir="ltr"><strong>(13.7, 29.2)</strong></p></td><td colspan="2"><p dir="ltr"><strong>P=0.0014</strong></p></td></tr><tr><td><p dir="ltr"><strong>Overall survival</strong></p></td><td>&nbsp;</td><td>&nbsp;</td><td colspan="2"><p dir="ltr"><strong>Hazard Ratio</strong></p><p dir="ltr"><strong>(95&nbsp;% CI)</strong></p></td></tr><tr><td><p dir="ltr"><strong>No. patients with event</strong></p></td><td><p dir="ltr"><strong>22</strong></p></td><td><p dir="ltr"><strong>33</strong></p></td><td colspan="2"><p dir="ltr"><strong>0.59 (0.35, 1.02)<br />p=0.0555</strong></p></td></tr></tbody></table><p dir="ltr"><strong>* defined as absence of any invasive cancer both in the breast and axillary nodes</strong></p><p>&nbsp;</p><p dir="ltr"><strong>An absolute benefit of 13 percentage points in favour of the Herceptin arm was estimated in terms of 3-year event-free survival rate (65&nbsp;% versus. 52&nbsp;%).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Subcutaneous formulation</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Study BO22227 was designed to demonstrate non-inferiority of treatment with Herceptin subcutaneous formulation versus Herceptin intravenous formulation based on co-primary PK and efficacy endpoints (trastuzumab Ctrough at pre-dose Cycle 8, and pCR rate at definitive surgery, respectively). A total of 595 patients with HER2-positive, operable or locally advanced breast cancer (LABC) including inflammatory breast cancer received eight cycles of either Herceptin intravenous formulation or Herceptin subcutaneous formulation concurrently with chemotherapy (4 cycles of docetaxel, 75 mg/m2 intravenous infusion, followed by 4 cycles of FEC ([5-Fluorouracil, 500 mg/m2; epirubicin, 75 mg/m2; cyclophosphamide, 500 mg/m2 each intravenous bolus or infusion]), followed by surgery, and continued therapy with Herceptin intravenous formulation or Herceptin subcutaneous formulation as originally randomized for 10 additional cycles, for a total of one year of treatment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The analysis of the efficacy co-primary endpoint, pCR, defined as absence of invasive neoplastic cells in the breast, resulted in rates of 40.7&nbsp;% (95&nbsp;% CI: 34.7, 46.9) in the Herceptin intravenous arm and 45.4&nbsp;% (95&nbsp;% CI: 39.2&nbsp;%, 51.7&nbsp;%) in the Herceptin subcutaneous arm, a difference of 4.7 percentage points in favour of the Herceptin subcutaneous arm. The lower boundary of the one-sided 97.5&nbsp;% confidence interval for the difference in pCR rates was -4.0, establishing the non-inferiority of Herceptin subcutaneous for the co-primary endpoint&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 12: Summary of pathological Complete Response (pCR)&nbsp;</strong></p><table><tbody><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Herceptin IV&nbsp;&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>&nbsp;(N = 263)</strong></p></td><td><p dir="ltr"><strong>Herceptin SC (N=260)</strong></p></td></tr><tr><td><p dir="ltr"><strong>pCR (absence ofinvasive neoplastic cells in breast</strong></p></td><td><p dir="ltr"><strong>107 (40.7%)</strong></p></td><td><p dir="ltr"><strong>118 (45.4%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>&nbsp; &nbsp; Non-responders</strong></p></td><td><p dir="ltr"><strong>156 (59.3%)</strong></p></td><td><p dir="ltr"><strong>142 (54.6%)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Exact 95% CI for pCR Rate*&nbsp;&nbsp;</strong></p></td><td><p dir="ltr"><strong>(34.7; 46.9)</strong></p></td><td><p dir="ltr"><strong>(39.2; 51.7)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Difference in pCR (SC minus IV arm)</strong></p></td><td colspan="2"><p dir="ltr"><strong>4.70</strong></p></td></tr><tr><td><p dir="ltr"><strong>Lower bound one-sided 97.5% CI for the difference in pCR**</strong></p></td><td colspan="2"><p dir="ltr"><strong>-4.0</strong></p></td></tr></tbody></table><p dir="ltr"><strong>*Confidence interval for one sample binomial using Pearson-Clopper method</strong></p><p dir="ltr"><strong>**Continuity correction of Anderson and Hauck (1986) has been used in this calculation</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Analyses with longer term follow-up of a median duration exceeding 40 months supported the non-inferior efficacy of Herceptin subcutaneous compared to Herceptin intravenous with comparable results of both EFS and OS (3-year EFS rates of 73% in the Herceptin intravenous arm and 76% in the Herceptin subcutaneous arm, and 3-year OS rates of 90% in the Herceptin intravenous arm and 92% in the Herceptin subcutaneous arm).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For non-inferiority of the PK co-primary endpoint, steady-state trastuzumab Ctrough value at the end of treatment Cycle 7, refer to section 5.2. Pharmacokinetic Properties. For the comparative safety profile see section 4.8.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The final analysis at a median follow-up exceeding 70 months showed similar EFS and OS between patients who received Herceptin IV and those who received Herceptin SC. The 6-year EFS rate was 65% in both arms (ITT population: HR=0.98 [95% CI: 0.74;1.29]) and the OS rate, 84% in both arms (ITT population: HR=0.94 [95% CI: 0.61;1.45]).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Study MO28048 investigating the safety and tolerability of Herceptin subcutaneous formulation as adjuvant therapy in HER2 positive EBC patients who were enrolled in either a Herceptin subcutaneous vial cohort (N=1868 patients, including 20 patients receiving neoadjuvant therapy) or a Herceptin subcutaneous administration system cohort (N=710 patients, including 21 patients receiving neoadjuvant therapy) resulted in no new safety signals. Results were consistent with the known safety profile for Herceptin intravenous and Herceptin subcutaneous formulations. In addition, treatment of lower body weight patients with Herceptin subcutaneous fixed dose in adjuvant EBC was not associated with increased safety risk, adverse events and serious adverse events, compared to the higher body weight patients. The final results of study BO22227 at a median follow-up exceeding 70 months were also consistent with the known safety profile for Herceptin IV and Herceptin SC, and no new safety signals were observed.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The European Medicines Agency has waived the obligation to submit the results of studies with Herceptin in all subsets of the paediatric population for breast cancer (see section 4.2 for information on paediatric use).</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>The pharmacokinetics of trastuzumab at a dose of 600&nbsp;mg administered three-weekly by the subcutaneous route was compared to the intravenous route (8&nbsp;mg/kg loading dose, 6&nbsp;mg/kg maintenance every three weeks) in the phase III study BO22227. The pharmacokinetic results for the co primary endpoint, Ctrough pre dose Cycle 8, showed non-inferiority of the Herceptin subcutaneous compared to the Herceptin intravenous dose adjusted by body weight.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The mean Ctrough during the neoadjuvant treatment phase, at the pre dose Cycle 8 time point, was higher in the Herceptin subcutaneous arm (78.7&nbsp;&micro;g/mL) than the Herceptin intravenous arm (57.8&nbsp;&micro;g/mL) of the study. During the adjuvant phase of treatment, at the pre-dose Cycle 13 time point, the mean Ctrough values were 90.4&nbsp;&micro;g/mL and 62.1&nbsp;&micro;g/mL, respectively. Based on the observed data in study BO22227, steady state with the intravenous formulation was reached at cycle 8. With Herceptin subcutaneous formulation, concentrations were approximately at steady-state following Cycle 7 dose (pre-dose Cycle 8) with small increase in concentration (&lt;15%) up to cycle 13. The mean Ctrough at the subcutaneous pre- dose cycle 18 was 90.7 &micro;g/mL and is similar to that of cycle 13, suggesting no further increase after cycle 13.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The median Tmax following subcutaneous administration was approximately 3 days, with high interindividual variability (range 1-14 days). The mean Cmax was expectedly lower in the Herceptin subcutaneous formulation (149 &mu;g/mL) than in the intravenous arm (end of infusion value: 221 &mu;g/mL).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The mean AUC021 days following the Cycle 7 dose was approximately 10&nbsp;% higher with the Herceptin subcutaneous formulation as compared to the Herceptin intravenous formulation, with mean AUC values of 2268&nbsp;&micro;g/mL&bull;day and 2056&nbsp;&micro;g/mL&bull;day, respectively. The AUC021 days following Cycle 12 dose was approximately 20&nbsp;% higher with the Herceptin subcutaneous formulation than the Herceptin intravenous dose, with mean AUC values of 2610&nbsp;&micro;g/mL&bull;day and 2179&nbsp;&micro;g/mL&bull;day, respectively. Due to the significant impact of body weight on trastuzumab clearance and the use of a fixed dose for the subcutaneous administration the difference in exposure between subcutaneous and intravenous administration was dependent on body weight: in patients with a body weight &lt; 51 kg, mean steady state AUC of trastuzumab was about 80% higher after subcutaneous than after intravenous treatment whereas in the highest BW group (&gt; 90 kg) AUC was 20% lower after subcutaneous than after intravenous treatment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>A population PK model with parallel linear and nonlinear elimination from the central compartment was constructed using pooled Herceptin SC and Herceptin IV PK data from the phase III study BO22227 to describe the observed PK concentrations following Herceptin IV and Herceptin SC administration in EBC patients. Bioavailability of trastuzumab given as the subcutaneous formulation was estimated to be 77.1%, and the first order absorption rate constant was estimated to be 0.4 day-1. Linear clearance was 0.111&nbsp;L/day and the central compartment volume (Vc) was 2.91&nbsp;L. The Michaelis-Menten parameter values were 11.9&nbsp;mg/day and 33.9&nbsp;&micro;g/mL for Vmax and Km, respectively. Body weight and serum alanine aminotransferase (SGPT/ALT) showed a statistically significant influence on PK, however, simulations demonstrated that no dose adjustments are required in EBC patients. The population predicted PK exposure parameter values (median with 5th - 95th Percentiles) for Herceptin SC dosing regimens in EBC patients are shown in Table 13 below.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Table 13 Population Predicted PK Exposure Values (median with 5th - 95th Percentiles) for the Herceptin SC 600&nbsp;mg Q3W Dosing Regimen in EBC patients</strong></p><p>&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>Primary tumor type and Regimen</strong></p></td><td><p dir="ltr"><strong>Cycle</strong></p></td><td><p dir="ltr"><strong>N</strong></p></td><td><p dir="ltr"><strong>Cmin</strong></p><p dir="ltr"><strong>(&micro;g/mL)</strong></p></td><td><p dir="ltr"><strong>Cmax</strong></p><p dir="ltr"><strong>(&micro;g/mL)</strong></p></td><td><p dir="ltr"><strong>AUC0-21days</strong></p><p dir="ltr"><strong>(&micro;g.day/mL)</strong></p></td></tr><tr><td rowspan="2"><p dir="ltr"><strong>EBC 600 mg Herceptin SC q3w</strong></p></td><td><p dir="ltr"><strong>Cycle 1</strong></p></td><td><p dir="ltr"><strong>297</strong></p></td><td><p dir="ltr"><strong>28.2</strong></p><p dir="ltr"><strong>(14.8 - 40.9)</strong></p></td><td><p dir="ltr"><strong>79.3</strong></p><p dir="ltr"><strong>(56.1 - 109)</strong></p></td><td><p dir="ltr"><strong>1065</strong></p><p dir="ltr"><strong>(718 - 1504)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Cycle 7 (steady state)</strong></p></td><td><p dir="ltr"><strong>297</strong></p></td><td><p dir="ltr"><strong>75.0</strong></p><p dir="ltr"><strong>(35.1 - 123)</strong></p></td><td><p dir="ltr"><strong>149</strong></p><p dir="ltr"><strong>(86.1 - 214)</strong></p></td><td><p dir="ltr"><strong>2337</strong></p><p dir="ltr"><strong>(1258 - 3478)</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>Trastuzumab washout</strong></p><p dir="ltr"><strong>Trastuzumab washout period was assessed following subcutaneous administration using the population PK model. The results of these simulations indicate that at least 95% of patients will reach concentrations that are &lt;1&nbsp;&mu;g/mL (approximately 3% of the population predicted Cmin,ss, or about 97% washout) by 7&nbsp;months.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Herceptin Intravenous&nbsp;</strong></p><p dir="ltr"><strong>There was no evidence of acute or multiple dose-related toxicity in studies of up to 6 months, or reproductive toxicity in teratology, female fertility or late gestational toxicity/placental transfer studies. Herceptin is not genotoxic. A study of trehalose, a major formulation excipient did not reveal any toxicities.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>No long-term animal studies have been performed to establish the carcinogenic potential of Herceptin, or to determine its effects on fertility in males.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Herceptin Subcutaneous&nbsp;</strong></p><p dir="ltr"><strong>A single dose study in rabbits and a 13-week repeat dose toxicity study in Cynomolgus monkeys were conducted. The rabbit study was performed to specifically examine local tolerance aspects. The 13-week study was performed to confirm that the change in route of administration and the use of the novel excipient recombinant human hyaluronidase (rHuPH20) did not have an effect on the Herceptin safety characteristics. Herceptin subcutaneous formulation was locally and systemically well tolerated.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Hyaluronidase is found in most tissues of the human body. Non-clinical data for recombinant human hyaluronidase reveal no special hazard for humans based on conventional studies of repeated dose toxicity including safety pharmacology endpoints.&nbsp; Reproductive toxicology studies with rHuPH20 revealed embryofetal toxicity in mice at high systemic exposure, but did not show teratogenic potential.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Recombinant human hyaluronidase (rHuPH20) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (2000 U/mL)</strong></p><p dir="ltr"><strong>L-histidine</strong></p><p dir="ltr"><strong>L-histidine hydrochloride monohydrate</strong></p><p dir="ltr"><strong>&alpha;,&alpha;-trehalose dihydrate</strong></p><p dir="ltr"><strong>L-methionine</strong></p><p dir="ltr"><strong>Polysorbate 20</strong></p><p dir="ltr"><strong>Water for injections</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Herceptin subcutaneous formulation is a ready to use solution which should not be mixed or diluted with other products.<br />No incompatibilities between Herceptin subcutaneous formulation and polypropylene or polycarbonate syringe material or stainless steel transfer and injection needles and polyethylene Luer cone stoppers have been observed</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                21 months.

Once transferred from the vial to the syringe the medicinal product is physically and chemically stable for 48 hours at 2°C – 8°C and subsequently 6 hours at ambient temperature (max. 30°C) in diffused daylight.
As Herceptin does not contain any antimicrobial-preservative, from a microbiological point of view, the medicine should be used immediately. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</strong></p><p dir="ltr"><strong>Do not freeze.</strong></p><p dir="ltr"><strong>Keep the vial in the outer carton in order to protect from light.</strong></p><p dir="ltr"><strong>Once removed from the refrigerator Herceptin subcutaneous formulation must be administered within 6 hours and should not be kept above 30&deg;C.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For storage conditions of the opened medicinal product, see section 6.3 and 6.6.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p dir="ltr"><strong>One 6&nbsp;mL clear glass type I vial with butyl rubber stopper laminated with a fluoro-resin film containing 5&nbsp;mL of solution (600&nbsp;mg of trastuzumab).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Each carton contains one vial.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Herceptin should be inspected visually to ensure there is no particulate matter or discolouration prior to administration.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Herceptin is for single-use only.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>As Herceptin does not contain any antimicrobial-preservative, from a microbiological point of view, the medicine should be used immediately. If not used immediately, preparation should take place in controlled and validated aseptic conditions. After transfer of the solution to the syringe, it is recommended to replace the transfer needle by a syringe closing cap to avoid drying of the solution in the needle and not compromise the quality of the medicinal product. The hypodermic injection needle must be attached to the syringe immediately prior to administration followed by volume adjustment to 5 mL.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                F. Hoffmann-La Roche Ltd, 
Grenzacherstrasse 124
CH-4070 Basel
Switzerland.
8.	MARKETING AUTHORISATION NUMBER(S)

289-24-18


9.	DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 24 April 2018

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                22 September 2021

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>